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Tuberculosis infects an estimated one-third of the world’s population, and is 
responsible for more deaths than any other single infectious agent. The continued success 
of Mycobacterium tuberculosis (MTB) in the post-antibiotic area can be attributed 
principally to pulmonary cavities: pathologic air spaces surrounded by scar tissue that 
have replaced healthy lung tissue. Cavities are the primary source of bacterial 
transmission during infection and contribute significantly to antibiotic resistance and 
treatment failure, yet the pathogenesis of cavitation is poorly understood. Proposed 
contributing factors include mechanical stress and enzymatic tissue destruction. To 
investigate these phenomena, we use a novel repetitive aerosol infection protocol in 
rabbits to produce a reliable model of tuberculous cavitation in which cavities are 
monitored by serial computed tomography. Using this model, we demonstrate that 
pharmacologic inhibition of collagenases does not reduce cavitation, contrary to their 
speculated role as drivers of cavitation. Using high-resolution 4D cavity maps to track 
cavity dynamics over time, we show that mechanical stress contributes significantly to 
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cavity formation and persistence dynamics. We also establish that central necrosis of the 
granuloma is a necessary precursor lesion, but is not sufficient in itself to cause 
cavitation. Finally, we examine the role of necrosis during infection and cavitation in 
C3HeB/FeJ mice – specifically, we probe the involvement of the RIP-kinase mediated 
programmed necrosis pathway. We demonstrate robust necroptosis activation in infected 
macrophages within and around granulomas in mice – the first in vivo demonstration of 
necroptosis induction during MTB infection. However, pharmacologic inhibition of RIP1 
– the key decision checkpoint in the necroptosis pathway - does not alter outcomes in this 
model, suggesting alternative activation by one of several RIP1 bypass pathways.  
In this thesis, we establish two optimized animal models for investigating the 
pathogenesis of cavitation, and show that these models are well-suited for screening of 
novel therapeutics. It is our hope that these models will be used in the future not only to 
further our understanding of the disease, but also to advance novel host-directed therapies 
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1.1 Thesis Statement 
Pulmonary infection with Mycobacterium tuberculosis leads to a spectrum of 
pathologic changes in the lung. The most consequential of these lesions is the pulmonary 
cavity: an abnormal air-filled space that has replaced functional lung tissue. Despite the 
immense importance of cavitation in the natural history of the disease, the mechanisms 
underlying pulmonary cavitation are poorly understood. Elucidation of these mechanisms 
is critical for the development of novel host-directed therapies that will work in 





Mycobacterium tuberculosis (MTB) is an ancient human pathogen. It has coevolved 
and traveled with human beings for millennia, peppering our history and our stories – 
never in the bombastic gruesome style of the Black Death, or the macabre spectre of 
hemorrhagic fever, but as the steady unseen hand quietly shaping the destiny of our 
species. This intimate relationship cultivated by MTB has garnered it a well-deserved 
reputation as the perfect human parasite 1.  
A cure for tuberculosis first arrived in the early 1940s with the discovery of 
streptomycin 2. Today, uncomplicated infections are treated with a combination of 
antibiotics (rifampin, isoniazid, pyrazinamide and ethambutol) for 6-9 months 2. This 
antibiotic regime has greatly reduced the burden of MTB in the developed world, moving 
it out of the public spotlight. Meanwhile, financial and practical barriers to treatment in 
poorer countries allow MTB to smolder unchecked and largely unseen in much of the 
world 2,3. As of 2016, the World Health Organization estimated that an astonishing one 
third of the world’s population was latently infected with Mycobacterium tuberculosis 3. 
MTB now competes with Human Immunodeficiency Virus (HIV) for the title of number 
one infectious killer 3,4.  
Why does tuberculosis continue to enjoy such success in the post-antibiotic era? 
Antibiotic resistance is a growing problem in many species of bacteria, and MTB is no 
exception 3. The long treatment times required to eliminate the infection often become 
burdensome to patients, causing them to prematurely terminate therapy once their clinical 
condition has improved 3. Premature cessation of therapy is a major contributor to 
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antibiotic resistance, allowing bacteria to “sample” an antibiotic and live to tell about it. 
Pockets of resistant bacteria also develop within necrotic granulomas and pulmonary 
cavities, whose walls of fibrous scar tissue prevent movement of both antibiotics and 
immune cells into the microbe-rich center 5,6. Contemporary research focuses not only on 
the development of novel antibiotics, but also on Host-Directed Therapies (HDTs) that 
work in conjunction with antibiotics to shorten treatment times and increase antibiotic 
penetration 7. 
Perhaps the larger question is that of transmission, which has been insufficiently 
addressed. MTB is transmitted from person to person by the coughing of bacteria-laden 
aerosol droplets from deep within the lung 2. The highest concentrations of bacteria in the 
infected lung are found within pulmonary cavities, which shelter them from antibiotics 
and the immune system 8. The center of a cavity frequently communicates with the 
bronchial tree, allowing bacteria to be expelled in large numbers (Figure 1.1). Thus, 
cavities represent the major route of transmission for MTB. Host-directed therapies 
targeting cavity formation have the potential to lessen the global TB burden by reducing 
transmission, antibiotic resistance and treatment failure. 
1.3 Historical Perspectives and Challenges 
The study of tuberculosis presents a set of unique challenges not faced by other 
disciplines. Perhaps most obviously, Mycobacterium tuberculosis is a dangerous 
pathogen that must be handled under Bio-Safety Level 3 conditions. MTB is transmitted 
via aerosols, and must be kept in carefully-maintained containment facilities to prevent 
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its escape. Researchers undergo extensive training and wear a full suit of personal 
protective equipment (PPE) at all times, including a respirator. Patients are maintained in 
careful isolation to prevent transmission to health care workers. Working with infected 
animals introduces additional levels of risk, with the possibility of bites and scratches that 
can breach PPE. These safety considerations increase both the financial cost as well as 
the practical difficulty of working with MTB. Additionally, many Mycobacteria (MTB 
notorious among them) are extremely slow-growing, with doubling rates of 
approximately 24 hours in the case of MTB 2. This corresponds to a sluggish bacterial 
metabolism, providing them with a measure of resistance against current antibiotics 
which target actively growing organisms 2. In patients, it takes 6-9 months of continuous 
multimodal antibiotic therapy to achieve sterilization 2. Both in vivo and in vitro, this 
translates into slow-moving experiments with long periods of waiting. A simple mouse 
monotherapy experiment (such as that described in Chapter 4) can be performed in 
approximately 12 weeks. More complicated animal studies involving combination 
antibiotic therapy and relapse may take up to a year to complete, and latency studies are 
often performed over the course of several years. 
Yet ironically, perhaps the greatest hindrance to TB research came in the form of 
Streptomycin, which so rapidly and efficiently removed Mycobacteria from the lungs and 
minds of wealthy westerners that it quickly condemned TB to the ranks of forgotten third 
world diseases. Research efforts declined precipitously in the second half of the 20th 
century following a steady decline in public funding. These were the “dark ages” of TB 
research which only came to an end when the 1980’s brought the Human 
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Immunodeficiency Virus (HIV) to the western world. MTB – far from eradicated - had 
been hiding quietly in America for the intervening years, maintained in conditions of 
poverty and overcrowding which cause a natural aversion of the attention. HIV generated 
a fresh pool of immunodeficient adults, setting the perfect stage for MTB to make its 
comeback.  
Large gaps still exist in our basic understanding of the bacterium and the disease it 
causes, with much of our foundational knowledge built on work from the early 20th 
century. Relying on literature of this period introduces additional obstacles as one 
attempts to decrypt the meaning of imprecise and archaic terms in the context of a 
modern understanding of molecular pathology. Particular difficulty comes when trying to 
accurately apply these terms in a discussion on TB immunology. For example, “latency” 
is described as a phenomenon whereby tubercle bacilli enter a dormant state in the host, 
reactivating years or even decades later 9. Yet clinically, latency is merely defined by a 
positive immune response to tuberculin proteins (whether by Manteaux or Interferon 
Gamma Release Assay) – tests which merely measure exposure to mycobacteria and are 
unable to discriminate between current and resolved infections, or even between TB 
infected and BCG-vaccinated individuals 9. Efforts to integrate historical and modern 
data under united terminology are ongoing 10. 
Access to patient samples was unparalleled in the first half of the 20th century, and 
carefully documented observations by pathologists such as Rich and Canetti are 
invaluable for a constructing a true picture of TB pathogenesis 11,12. However, when one 
considers the natural course and potential outcomes of tuberculosis, it becomes clear that 
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such autopsy data segregates neatly into two patient populations: (A) Those with 
fulminant tuberculosis who died of their disease, and (B) those with latent or resolved 
tuberculosis who died of something else entirely. Thus, the inherently biased nature of 
post-mortem patient data leaves us with an incomplete picture, and emphasizes the 
critical importance of developing animal models in which all stages of the disease can be 
replicated under controlled conditions. 
1.4 Animal Models of Tuberculous Cavitation 
Primates. Historically, research into the mechanisms of cavitation has been hindered 
by a lack of animal models that reliably reproduce the pathology of the disease as seen in 
humans 13. The human response to MTB infection is remarkable for its extreme 
heterogeneity, both between and within patients. Disease manifestations are highly 
variable, and a diverse spectrum of lesions is often observed within the lungs of a single 
patient 12,14. Because of this extreme variability, no single animal model recapitulates all 
aspects of the human disease, with the possible exception of our closest relatives, 
nonhuman primates (NHPs). As in much of biomedical research, NHPs could perhaps be 
considered the gold standard model of pulmonary tuberculosis, although significant 
obstacles limit their usefulness as a model of TB cavitation. Similar to their human 
counterparts, NHPs develop cavities sporadically and at a low frequency, though their 
large size permits advanced imaging techniques such as CT and MRI. Although the 
relatively longer lifespan of primates facilitates collection of valuable cohort data over 
time, the low numbers of animals used often limits the generalizability of such studies. 
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Finally, practical and financial considerations such as animal availability, handling, study 
design and BSL3 housing are major limiting factors in the use of primates. Because of 
these obstacles, no systemic studies of cavitation have been undertaken in primate models 
to date. 
Rabbits. The rabbit has been used to model several aspects of TB disease, and gained 
scientific popularity in the 1950s with Lurie’s characterization of genetically susceptible 
and resistant inbred rabbit populations 15. Cavitation was documented sporadically in 
these early rabbit models, and only after long periods (6-10 months) 16. Lurie’s inbred 
lines were unfortunately not maintained, and modern rabbit studies use outbred rabbits 
such as the New Zealand White, which have a high natural resistance to MTB. 
Mycobacterium bovis is thus frequently used to model tuberculosis in rabbits due to its 
relatively higher virulence in this species. Unlike MTB, M. bovis results in fulminant 
pulmonary disease in rabbits and therefore a more rapid onset of cavitation 17. Using M. 
bovis in outbred rabbits, Dannenberg advanced the work of Lurie by characterizing the 
role of cell-mediated immunity (CMI) and delayed type hypersensitivity (DTH) in cavity 
generation 18, confirming cavitation as an immune-mediated event. However, M. bovis 
also frequently results in disseminated disease in multiple species including rabbits 19,20 – 
a phenomenon not typically seen in human TB except in cases of altered immune 
function 12. As cavity generation in TB patients is correlated with immune status 21, the 
utility of the aerosol M. bovis model for interrogating the pathogenesis of cavity 
generation is uncertain. Kübler further modified this model by pre-sensitizing animals 
with intradermal heat-killed M. bovis prior to bronchoscopic delivery of live M. bovis 
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into a single lung lobe, reliably producing a single large cavity at the site of inoculation 
22. The reproducibility and application of advanced imaging techniques makes this model 
valuable for investigating the local environment and life cycle of pulmonary cavities. The 
Kübler model greatly advanced our understanding of pulmonary matrix degradation 
during infection 23,24, but has been criticized for its highly artificial method of cavity 
induction. Chapter 2 introduces a novel method of repetitive aerosol MTB infection that 
reliably induces a high frequency of cavitation in rabbits 25. By utilizing aerosolized M. 
tuberculosis rather than M. bovis, rabbits more faithfully reproduce the human disease, 
generating a heterogeneous spectrum of pulmonary lesions with infrequent 
extrapulmonary spread. In Chapter 3, we use serial high resolution imaging in this model 
to interrogate the dynamics of cavity formation over the course of infection. A major 
disadvantage of any rabbit model is the limited availability of immunologic reagents, as a 
preponderance of commercial antibodies are produced in rabbits. 
Mice. Known prerequisites for cavitation include the induction of a strong DTH 
response 18 and the onset of necrosis 26 – two characteristics that are lacking in mouse 
models of TB infection in commonly used mouse strains C57BL/6 and BALB/c. Upon 
challenge with MTB, these mice develop solid cellular granulomas that lack necrosis or 
caseation, making them unsuitable models of human TB pathology 27. The recent 
characterization of the C3HeB/FeJ mouse – a general purpose immunocompetent strain 
that responds to TB infection by forming large caseating granulomas 28 – has brought 
mice once again to the forefront of tuberculosis research. In further support of the close 
association between necrosis and cavitation, these mice also have a high incidence of 
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pulmonary cavitation 29, making them the first rodent model of cavitation. An obvious 
advantage of this model is that is highly amenable to genetic manipulations – a factor 
already being exploited by several investigators to uncover genetic determinants of host 
necrosis during TB infection 30–32. In Chapter 4, we use the C3HeB/FeJ mouse to 
investigate the molecular determinants of host necrosis and the involvement of 
programmed cell death pathways. 
1.5 Comparative Pathology of Cavitation 
Spatial. The most obvious facts are the ones most often taken for granted. It often 
goes without saying that cavitation is a phenomenon unique to the lung. Yet this high 
locational selectivity reveals important insights about the pathogenesis of cavity 
formation that are infrequently discussed. Unlike other solid organs, the lung is 
constantly being subjected to fluctuating pressures and tension forces within the thoracic 
cavity. Constant negative pressure in the pleural space maintains the lungs in an inflated 
state, similar to a balloon in a bell jar 33. During inspiration, expansion of the chest wall 
and relaxation of the diaphragm cause this negative pressure to increase, pulling the lungs 
open and allowing air to flow in passively 33. This repetitive mechanical stress is not 
experienced by other internal organs, and contributes significantly to cavity formation 26. 
Healthy lung tissue contains a mixture of collagen and elastin, which provide structural 
integrity and elastic recoil, respectively 19. In diseased lung tissue, this matrix has been 
replaced by fibrovascular scar tissue which has reduced tensile strength and very little 
elasticity 19. In chapter 3, we examine the distribution and behavior of pulmonary cavities 
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in rabbits, and present additional evidence that mechanical action promotes cavity 
formation by disrupting the walls of necrotic pulmonary granulomas. 
Structural. Although frequently thought of as a characteristic finding, pulmonary 
cavities are by no means pathognomonic for tuberculosis. A diverse set of diseases – 
ranging from other infectious diseases to primary lung cancers – may result in pulmonary 
cavities, though of these MTB has the highest incidence 21. Despite their etiologic 
diversity, a survey of cavitary diseases for commonalities reveals that cavitary lesions 
share certain structural requirements. First, the interior of the lesion must be soft or 
liquefied, composed of necrotic debris which can escape into adjacent airways. Secondly, 
the exterior of the lesion must be structurally solid, so that it remains behind when the 
necrotic center is removed to form the wall of the cavity. Central necrosis often occurs in 
aggressive lung tumors (such as squamous cell carcinoma) as they outgrow their blood 
supply. As the tumor enlarges, necrotic debris drains into eroded airways, leaving behind 
an air-filled cavity with a wall composed of living tumor cells. A similar process occurs 
in subacute to chronic bacterial and fungal pneumonias. In the case of Klebsiella 
pneumoniae, which causes a subacute to chronic necrotizing pneumonia, large pus-filled 
abscesses are formed in the lung, which drain to leave behind a wall of scar tissue and 
inflammatory debris 21. Chronicity seems to play an important role in determining 
whether or not a cavity will form by virtue of how much scar tissue has accumulated 




Immunologic. In contrast to the granuloma, relatively little is known about the 
regional immunology of the cavity. CD4+ T cells were implicated as critical participants 
in the cavitation process when it was noticed that the incidence of cavitation is inversely 
correlated with declining CD4+ counts in HIV+ patients – not only for tuberculosis, but 
also for other common opportunistic infections 21. In these cases, your risk of cavitation 
actually decreases as your risk of infection and severe disease increases. An explanation 
for this can be gleaned from serum cytokine abnormalities in patients with cavitary 
disease. Interleukin-4 (IL-4) increases in patients with advanced disease 2 and is also 
correlated with the extent of cavitation 34,35. (Although importantly, we demonstrate in 
Chapter 3 that these two conditions are not necessarily correlated). Protective immunity 
to tuberculosis depends on a strong pro-inflammatory Th1 polarized response with robust 
production of IFNγ and TNFα. Conversely, failed immunity is associated with Th2 
polarization and a shift to IL-4 and TGFβ production, creating a more tolerigenic 
environment that favors bacterial proliferation and drives immunopathology 2. These 
systemic changes are similarly reflected at the level of the individual lesions, with each 
granuloma harboring a distinct Th1-Th2 balance 36,37. Cavitary lesions are characterized 
by interior depletion of lymphocytes and high levels of bacterial replication. In this sense, 
a cavity represents a regional instance of failed immunity, although much remains to be 
learned about how this failure occurs 38. 
Enzymatic. Multiple proteolytic enzymes have been implicated in the pathogenesis 
of tuberculous cavitation by their spatial upregulation in and surrounding cavities 24,39. 
Once unleashed, these collagenases and cathepsins initiate proteolytic cascades with high 
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destructive potential, making them attractive scapegoats in the pulmonary destruction that 
accompanies cavitation. However, teasing apart their role as either active drivers of 
cavitation or secondary responders to tissue damage has not yet been possible 25. As we 
discuss in the following two chapters, it is likely that the truth lies somewhere between 






Figure 1.1: The current model of cavity formation involves granuloma liquefaction and airway invasion.  
(A) Granuloma formation begins with an aggregate of activated macrophages, multinucleated giant cells, 
lymphocytes and neutrophils. (B) As the lesion enlarges, the center may undergo progressive necrosis, 
liquefaction and inspissation, resulting in the characteristic “caseous" appearance. (C) Formation of a 
variably thick outer capsule of fibroblasts and collagen occurs with chronicity. (D) If a large necrotic lesion 
arises in proximity to an airway, proteolytic enzymes in the necrotic center may lead to erosion into the 
bronchial tree. (E) Expulsion of necrotic contents into the airway leave behinds a thick-walled air-filled 




Repetitive Aerosol Exposure 
Promotes Cavitary Tuberculosis and 
Enables Screening of Host-Directed 
Therapies 
2.1 Authorship note 
This chapter represents the combined efforts of Drs. Elizabeth Ihms and Michael 
Urbanowski.  The double-exposure experiments were conceptualized and designed by 
MEU, and performed with assistance from EAI.  For the MMP inhibition studies, all 
animal studies were jointly designed and performed by MEU and EAI.  LC/MS-MS work 
was performed by MEU with help from KB and SL, and histopathology quantification 




Tuberculosis (TB) is a major cause of morbidity and mortality worldwide, with an 
estimated 10.4 million new cases of TB and 1.4 million deaths occurring in 2015 1. 
Individuals with active disease develop a spectrum of gross lesions including diffuse 
pulmonary inflammation, organized granulomas or “tubercles,” caseous granulomas, and 
cavities. The most consequential of these lesions is the pulmonary cavity. While not 
specific to TB, cavities are the greatest risk factor for transmission of tuberculosis bacilli 
2–5. Cavitary TB is also more difficult to treat than noncavitary disease, and is associated 
with the emergence of drug resistant infections 6. For patients with cavities who have 
been cured of TB, their cavities often remain, creating a niche for opportunistic infections 
7. Cavitary lesions that do resolve are associated with fibrotic scarring and reduced long-
term pulmonary function 8,9.  
A perfect storm of pathologic landscapes coincides within cavities to drive 
transmission and reduce the likelihood of treatment success. The interior surface of the 
cavity represents a well-oxygenated and immune privileged site that permits high levels 
of extracellular bacterial proliferation 6,10. Moreover, cavities frequently communicate 
with adjacent conducting airways, providing a perfect physical conduit for aerosolization 
and transmission 11. Finally, scar tissue and widespread necrosis within the cavity wall 
reduce the penetration of chemotherapeutic drugs, promoting antibacterial resistance 12–
15. Despite the importance of cavities to the natural history of TB, the mechanism of 
cavity formation in TB remains unclear. Histologically, cavities are thought to arise from 
necrotic granulomas, whose centers are both devoid of extracellular matrix. Pulmonary 
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extracellular matrix is composed primarily of collagen and elastin, which provide 
mechanical support to the lung while maintaining compliance and elasticity. The 
expression of collagenases leads to caseation, suggesting that collagen depletion may be 
an early mechanistic driver of cavitation 16–18. Indeed, increased expression of 
collagenases is also associated with cavity formation in both animal models and patients 
with TB 19, 20.  
A major limitation to studying cavitary tuberculosis has been the lack of reproducible 
animal models. Mice and guinea pigs rarely develop cavities, whereas they do occur in 
nonhuman primate and rabbit models 21–23. Previous studies in rabbits have employed 
pre-sensitization with heat-killed tubercle bacilli followed by a high-dose aerosol, 
transthoracic, or intrabronchial challenge 24–26. While these methods result in cavitation in 
some animals, they also generate extensive regional pneumonia, making it difficult to 
monitor granuloma formation, necrosis, and progression to cavity formation. 
Here we describe a novel model for cavitary TB based on repeated aerosol exposure 
in rabbits. This model reliably generates multiple cavitary foci in 60%–80% of study 
animals in a short period of time. Compared with single exposures of the same total 
bacterial burden, repetitive exposure generates more advanced disease and more cavitary 
foci, suggesting that repetitive exposure to aerosolized bacilli may be an important 
determinant of disease severity in high-incidence settings. Recently, the number of 
exposures experienced by newly infected TB patients was reported as a risk factor for 
disease progression 27. This model reliably develops human-like pulmonary cavities 
where matrix depletion is a major pathologic feature of cavity development. Finally, we 
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have applied this model to screen cipemastat, a potent inhibitor of matrix 
metalloproteinase-1 (MMP-1), as a potential host-directed therapy to limit the extent of 
tuberculous cavitation 28,29. 
2.3 Methods 
Infection of Rabbits. All procedures involving live animals were conducted in 
accordance with protocols approved by the Institutional Animal Care and Use Committee 
at the Johns Hopkins University School of Medicine. Adult female New Zealand White 
rabbits (2.5–3.5 kg) were purchased from Robinson Services (Mocksville, North 
Carolina) and individually housed in a Biosafety Level 3 facility without cross-
ventilation. Rabbits were infected in a Madison aerosol droplet generation chamber 
(College of Engineering Shops, University of Wisconsin, Madison). The aerosol 
inoculum for the chamber was prepared by dilution of log-phase bacterial culture of M. 
tuberculosis H37Rv to the appropriate optical density (OD) for each experimental group. 
Cipemastat Dosing. Cipemastat was obtained from the Roche Corporation (Basel, 
Switzerland), and the identity of the compound was confirmed by liquid chromatography 
and tandem mass spectrometry (LC/MS-MS). Rabbits in the treatment group were given 
100 mg/kg cipemastat orally by body weight using PediaSure as a vehicle. The 
concentration of cipemastat in the vehicle was 100 mg/mL. Cipemastat treatment and 
vehicle shams were administered daily during study weeks 5–11. 
Pharmacokinetic Analysis of Cipemastat in Plasma. Three rabbits were given a 
single 100 mg/kg oral dose of cipemastat. Peripheral blood samples were collected every 
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30 minutes, then at 4, 6, 8, 12, and 24 hours. Experimental samples were analyzed in 
tandem with a standard curve prepared in untreated rabbit plasma. Plasma concentrations 
of cipemastat were detected and quantified by liquid chromatography–tandem mass 
spectrometry (AB SCIEX QTRAP 5500). Liquid chromatography was carried out by 
reverse-phase gradient elution between 90% mobile phase A (0.1% formic acid in water) 
and 95% mobile phase B (100% acetonitrile) over 2 minutes on a ZORBAX Eclipse Plus 
C18 column (2.1 × 50 mm, 3.5 μm, Agilent Technologies). Selected ion monitoring of 
the cipemastat parent ion at m/z 437.2 identified daughter ions at m/z 262.2 and 404.3. 
These transitions were supported by predicted masses in a cipemastat fragmentation map 
and agree with transitions identified by Hopfgartner et al 30. Cipemastat concentration in 
eluate was measured as the area under the curve for mass transition peaks. Analysis was 
conducted using Analyst (SCIEX) and companion software MultiQuant (SCIEX). 
Pharmacokinetic (PK) analysis of total drug exposure over time (AUC0-24), half-life 
(T1/2), concentration maximum (Cmax), and time of concentration maximum (Tmax) 
were calculated using 2-compartment first-order PK analysis with WinNonlin software 
(version 7.0, Pharsight Corp).  
Computed Tomography. Rabbits were sedated with intramuscular injections of 
xylazine (3 mg/kg), ketamine (25 mg/kg) and acepromazine (1 mg) prior to 
bronchoscopically–assisted intubation with a 3.5 mm endotracheal tube (Teleflex 
Medical, Research Triangle Park, NC). Following intubation, animals were imaged using 
a CereTom 8-slice clinical computed tomography (CT) scanner with a 32.5-cm bore 
diameter (NeuroLogica, Boston, Massachusetts). To achieve reconstructions in the 
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absence of motion artifact, breath-holding was performed during CT scans as previously 
described by Kübler 31. Briefly, anesthetized rabbits were maintained at physiologic peak 
inspiration for approximately 15 seconds during image acquisition. 
Identification of Cavities From CT Reconstructions. Raw CT scan data was 
compiled into DICOM files using Loening Amide (Version 0.9.0). CT reconstructions 
were analyzed using VivoQuant software (Invicro). Pulmonary cavities were 
radiologically identified from CT scan reconstructions as a contiguous set of volume 
elements (voxels) with densities close to air (–1000 to 910 Hounsfield units [HU]) and 
encapsulated by consolidation, defined as a continuous region of voxels with densities 
similar to water (–725 to 1000 HU). This radiological definition was consistent with the 
consensus definition for cavities advanced by Gadkowski and Stout 2. Contiguous 
airspace and consolidation regions were selected by connected thresholding in the density 
range for each landmark.  
Necropsy and Histopathology. IM sedation was performed as previously described, 
after which animals were euthanized with 2-3cc IV pentobarbital solution in the marginal 
ear vein. Gross images of the lungs were obtained using a Nikon D3200 digital camera 
and a Nikon NIKKOR lens and analyzed with ImageJ to identify the areas of visually 
diseased lung as a fraction of the total area of splayed lung 32. Lungs were then gently 
infused with intratracheal 10% neutral buffered formalin prior to fixation for 48 hours. 
Transverse lung slices were processed for paraffin embedding and histologic sectioning. 
Serial 5 μm sections were stained using hematoxylin and eosin, Masson’s trichrome stain, 
or acid-fast stain. Image capture for semiquantitative trichrome quantification was 
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performed on a Nikon Eclipse 90i microscope with attached Nikon DS-Ri1 color camera, 
and analyzed using NIS Elements Advanced Research software (Nikon Instruments, 
Melville, New York). Regions of interest (ROI) included the full thickness of the cavity 
wall while excluding necrotic debris and air space at the cavity interior. Positive staining 
was calculated as a percentage of the total ROI. 
Substrate Cleavage Assay. Recombinant human MMP-1 (BioVision, Milpitas, 
California) was added to a solution of type I collagen (Thermo Fisher Scientific, 
Waltham, Massachusetts) in phosphate-buffered saline at a molar ratio of 1:5. One 
hundred microliters of Novex Zymogram 1X Developing Buffer (Thermo Fisher 
Scientific, Waltham, Massachusetts) with or without 1 μg cipemastat was added to this 
solution prior to incubation at 37°C for 24 hours. At 24 hours, an equal volume of 
ethylenediaminetetraacetic acid (EDTA) was added to stop the cleavage reaction, and the 
products were briefly boiled and subjected to sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis on a Mini-Protean TGX precast gel (Bio-Rad, Hercules, California). 
2.4 Results 
Repetitive aerosol exposure to M. tuberculosis causes a high frequency of 
cavitation in a rabbit model. Sensitization of animals by injection of heat-killed 
mycobacteria prior to infection increases the frequency and severity of cavitation in 
rabbit models 26,31. We reasoned that multiple aerosol challenges with virulent M. 
tuberculosis would provide a robust and sustained immune-sensitizing effect by 
simultaneously antagonizing both innate and adaptive defenses, thereby increasing cavity 
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generation. To test this hypothesis, we infected rabbits with M. tuberculosis using two 
different exposure patterns. For our studies, we defined exposure as the product of the 
bacterial concentration in the aerosol inoculum and the total time spent in the aerosol 
chamber. One group of rabbits received five aerosol challenges with M. tuberculosis at an 
optical density (OD600) of 0.05 over a 2-week period. A second group of rabbits 
received a single aerosol challenge with M. tuberculosis at an OD600 of 0.25, five times 
that of the repetitive exposure (Figure 2.1A). Each challenge corresponded to a bacterial 
implantation of approximately 400 colony-forming units (CFUs) per exposure in the OD 
0.05 group, and 2200 CFUs per exposure in the OD 0.25 group (Figure 2.2). We 
established that the cumulative exposure was the same for both groups by measuring the 
CFUs in the aerosol inoculum (Figure 2.1A). To confirm that concentrations of bacilli are 
linearly correlated with the OD of the aerosol inoculum, we performed a titration assay to 
compare the inoculum OD with the day one implantation of bacteria in the lungs, and 
showed a linear correlation in the OD range used in these experiments (Figure 2.2). Our 
data indicate that it is likely that repetitive exposure rabbits were inoculated on every 
occasion of exposure, as bacteria were reliably recovered from the lungs of all animals in 
the lowest exposure group (Figure 2.2). 
Cavity development was monitored using serial computed tomography. 75% (3/4) of 
the animals in the repetitive exposure group developed at least one cavity, vs. 25% (1/4) 
of the animals in the single exposure group (Figure 2.1B). Of the animals that cavitated, 
those in the repetitive exposure group developed more cavities per animal than those in 
the single exposure group (Figure 2.1C). By 10 weeks post-infection, animals in the 
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repetitive aerosol group experienced worse lung disease than those in the single exposure 
group (Figure 2.1D and Figure 2.3). These data demonstrate that repetitive exposure 
results in an increase in the severity of disease as well as the frequency and severity of 
cavitation.  
Cavities from repetitive exposure form quickly, show dynamic behavior, and 
often persist for many weeks. To study the dynamics of cavity formation generated by 
repetitive exposure to M. tuberculosis, eight rabbits were infected with M. tuberculosis 
using the repetitive exposure protocol and monitored by serial CT scans. The overall 
frequency of cavitation in this study was 87% (7/8), further supporting our previous 
observations with the repetitive exposure method (Figure 2.4A). The greatest increase in 
the frequency of cavitation occurred between weeks 6 and 8, during which time the 
frequency of cavitation increased from 11% (1/8) at week 6 to 50% (4/8) at week 8 
(Figure 2.4A). Between weeks 8 and 16, the frequency of cavitation increased modestly 
to 63% (5/8), but was also marked by the occasional resolution of existing cavities and 
the generation of new cavities. Three-dimensional CT reconstructions of the lungs were 
analyzed to evaluate changes in cavity morphology over time. From this analysis, we 
identified 3 patterns of change in cavity morphology: (1) growth (Figure 2.4B and 2.4C, 
examples 1, 2, and 3); (2) shrinkage (Figure 2.4B and 2.4C, examples 2 and 3); and (3) 
resolution (Figure 2.4B and 2.4C, example 4). Together, these data demonstrate that the 
peak of cavitation occurs between 6 and 8 weeks after initial aerosol exposure, and that 
cavities are persistent and dynamic structures.  
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Central necrosis and matrix depletion are prerequisites for cavitation. A large 
body of historic literature, in addition to our own observations, demonstrates that 
tuberculous cavities arise from necrotic granulomas. To further characterize cavities 
generated by repetitive exposure to M. tuberculosis, we investigated whether the 
pathologic phenotype of lung destruction was similar to that observed in the human 
disease. Histologically, lungs from rabbits infected by repetitive exposure display many 
of the microscopic findings described in patient autopsy reports (Figure 2.5A) 10,21,33,34. 
These hallmarks include granulomas, necrotic granulomas, and cavities. Histologic 
observations from the repetitive exposure model demonstrate similar cytoarchitecture 
between necrotic granulomas and cavities, further supporting a close relationship 
between these lesions (Figures 2.5A, 2.5B, and 2.6C). The cavities generated by 
repetitive exposure were marked by large proliferations of acid-fast bacteria along their 
inner surface and an outer fibrotic wall (Figure 2.5B). Because our investigations are 
predicated on the pathologic observation that matrix depletion predisposes to cavitation, 
we also confirmed that collagen depletion was a hallmark of cavitary lesions from 
repetitive exposure (Figure 2.6). These observations show that repetitive aerosol exposure 
in rabbits generates a spectrum of histologic lesions commonly observed in human TB 
pathology, and validates the model for investigation of pathologic matrix depletion.  
The collagenase cipemastat is orally bioavailable in rabbits and reaches 
therapeutic concentrations in peripheral blood. Cipemastat is a potent inhibitor of 
MMP-1 and was originally developed by the Roche Corporation as an antiarthritis agent 
28,29. We confirmed that cipemastat inhibits MMP-1 in vitro (Figure 2.7) and has no 
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intrinsic antimycobacterial activity (Table 2.1). To confirm that cipemastat is orally 
bioavailable in rabbits and had suitable kinetics for a daily dosing regimen, we conducted 
a 3-rabbit pharmacokinetic study. Rabbits were given a single 100 mg/kg oral dose of 
cipemastat, a dose previously shown to be within the tolerability and efficacy range in 
human and animal studies 35,36. Peripheral blood samples were taken at regular intervals 
over a 24 hour period, and analyzed by LC/MS-MS. The results of the PK study showed 
an AUC 0-24hr of 21.79 h × μg/mL (49.9 μM × h), consistent with previously published 
oral dosing studies (Table 2.2, Figure 2.8) 35,36. Importantly, we found that the plasma 
concentration remained above the published half maximal inhibitory concentration 
(IC50) of 26 ng/mL (60 nM) for 22 of 24 hours following a single oral dose (Table 2.2 
and Figure 2.8) 28. These results demonstrate that cipemastat is orally bioavailable in 
rabbits and confirms that a daily dosing regimen is sufficient to maintain plasma 
concentrations above the IC50. 
 
Concentration  128 64 32 16 8 4 2 1 0.5 0.25 
cipemastat-1 % inhibition -5.61 -6.06 -2.32 -1.69 -4.30 -5.38 1.34 -5.84 -1.33 -8.56 
cipemastat-1 raw counts 57234 57491 55483 55099 56514 57133 53420 57374 54842 58848 
cipemastat-2 % inhibition 1.91 -1.78 3.10 -0.15 0.93 3.20 -0.99 -3.66 -0.04 -0.94 
cipemastat-2 raw counts 53132 55071 52479 54228 53634 52415 54664 56123 54196 54733 
cipemastat-3 % inhibition -3.85 -1.71 -1.33 4.02 2.77 5.75 9.50 -0.69 2.51 6.84 
cipemastat-3 raw counts 56208 55049 54836 52010 52623 51006 48971 54460 52777 50408 
Concentration  1.28 0.6 0.32 0.16 0.08 0.04 0.02 0.01 0.005 0 
isoniazid % inhibition 96.62 95.96 91.98 88.79 86.93 86.14 83.78 80.32 74.18 -3.01 
 raw counts 8742 6734 6906 7048 7561 7703 8814 10668 13971 55736 
Table 2.1: Results of Alamar Blue assay showing M. tuberculosis H37Rv growth in the presence of varying 




 AUC0-24 (hr*µg/mL) Cmax (µg/mL) Tmax (hr) T1/2 (hr) 
cipemastat 19.92 (16.42-23.44) 3.02 (1.99-4.44) 2.47 (1.98-3.07) 1.87 (1.22-2.23) 
Table 2.2: Pharmacokinetic data for cipemastat in rabbit plasma following bolus dosing. 
Cipemastat monotherapy does not protect against extensive lung destruction or 
cavitation. MMP-1 transcripts accumulate within regions of M. tuberculosis–induced 
lung damage, suggesting that MMP-1 activity may drive tissue destruction during 
infection 19. We thus hypothesized that inhibition of MMP-1 would mitigate cavity 
development (Figure 2.5C). We randomized 18 rabbits into an 8-rabbit vehicle group and 
a 10-rabbit cipemastat group. Animals in the cipemastat group received 100 mg/kg of 
cipemastat orally in PediaSure from weeks 5 through 11 post infection. This treatment 
window includes the weeks preceding the predicted onset of cavitation during which 
matrix depletion is occurring in lesions (Figure 2.10). Breath-hold CT scans were 
performed on all study animals at weeks 5, 7, 9, 11 and 14. These CT scans revealed no 
significant difference in the number or size of cavities between the control and treatment 
groups throughout the study, though cipemastat-treated animals showed a trend towards 
more severe cavitary disease (Figure 2.10 and 2.11).  
Collagen content of cavity walls is unchanged by cipemastat treatment. 
Tuberculosis lung lesions are often encircled by a fibrotic wall 21. This pathologic matrix 
deposition is also a feature of rabbits modeling cavitary TB (Figures 2.5B and 2.10D). As 
cipemastat inhibits the activity of collagenases, we predicted that cipemastat 
administration would increase the collagen content around TB lesions. Formalin-fixed 
paraffin-embedded 5um lung sections were stained with Masson’s trichrome for collagen. 
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Hue-thresholding was then used to quantify the amount of collagen within and around 
lesions. Surprisingly, there was no difference in the amount of collagen deposition 
between treated and control animals, suggesting that cipemastat treatment does not alter 
the course of pathologic collagen deposition around cavities in the rabbit model (Figure 
2.10D). 
2.5 Discussion 
We have developed a novel model for cavitary TB based on repeated aerosol 
exposure to virulent M. tuberculosis. Our data show that repetitive exposure over a 2-
week period produces more advanced disease and more cavities than a single exposure, 
even when adjusting the concentrations of bacteria to provide the same total exposure 
between groups. This finding suggests a link between repetitive exposure and TB 
exacerbation and is further supported by recent epidemiological evidence that multiple 
exposures to infected contacts increases the risk of TB progression 27. An association 
between repetitive exposure and severe TB may have important implications for 
epidemiology and infection control in high-incidence countries 37. Our experiments did 
not evaluate the mechanism of repetitive exposure–related disease exacerbation; 
however, it is likely that the driver of more severe disease in repeatedly exposed animals 
is repeated priming of cell-mediated immunity. Repetitive exposure may cause a 
cascading set of T-cell priming and expansion events that disproportionately exacerbate 
the immune response against M. tuberculosis antigen in the lung 38. Modeling cavitary 
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TB by repetitive aerosol exposure also models a spectrum of human lesions and 
pathologic matrix depletion associated with caseous and cavitary pulmonary TB 39.  
We took advantage of this model to screen cipemastat, a potent inhibitor of MMP-1, 
as an potential host-directed therapy to decrease cavitation 28. Our study was supported 
by a molecular phenotype in which MMP-1 expression increased around tuberculous 
lesions with matrix destruction 19. In these experiments, we administered cipemastat for 4 
weeks preceding the development of caseous and cavitary lesions in the repetitive aerosol 
model. However, treated animals did not show a reduction in cavitation or disease 
severity. As part of our investigations, we confirmed that the plasma concentrations of 
cipemastat were well above the IC50 during the 24-hour dosing cycle. We did not sample 
the concentration of cipemastat in TB lesions, so it is possible that cipemastat did not 
reach inhibitory concentrations within granulomas undergoing matrix destruction. 
Furthermore, MMP activity may be highly localized in pericellular niches or otherwise 
sequestered from chemotherapeutics 40. Alternatively, MMP-1 may act in conjunction 
with other extracellular collagenases to drive matrix depletion, reflecting redundancy in 
the proteolytic cascade. Finally, it is possible that MMP-1 is not a mediator of matrix 
depletion and cavitation. The increased expression of MMP-1 at TB lesions may be 
purely associative or indicate another role for MMP-1 in the pathobiology of TB. Our 
results demonstrate an entirely new model system to study tuberculous cavities. We show 
that repetitive exposure to aerosolized M. tuberculosis produces a pathologically relevant 






Figure 2.1: Infection parameters and disease patterns for rabbits challenged in the single exposure group 
and the repeated exposure group. 
(A) Experimental exposure conditions and timing. Single exposure group rabbits received a single 
implantation with approximately 2500 bacteria on day 8 and sham exposures to aerosolized PBS on days 1, 
4, 12 and 16. Repeated exposure group rabbits received five repeated exposures resulting in implantation of 
approximately 500 bacteria on each of days 1, 4, 8, 12 and 16. Exposure was calculated based on the CFU 
in the aerosol inoculum. The repeated exposure was calculated as the sum of the CFU/mL on each day of 
infection. (B) Frequency of cavitation among rabbits in the single exposure group and repeated exposure 
group. Cavities were identified by CT scan segmentation analysis as lung volumes not connected to the 
normal bronchial structure with densities between -875 and -1024 Hounsfield units, consistent with air. (C) 
The number of cavities per animal in the single exposure group and the repeated exposure group. Cavity 
counts are only plotted for the animals that demonstrated cavitation. (D) Quantification of the fraction of 





Figure 2.2: Titration of bacterial concentration in aerosol inoculum mapping optical density (OD) of 
aerosol inoculum to day-1 CFU recovered from rabbit lungs. 
(A) Experimental outline. (B) Bacteria recovered from rabbit lungs reported by OD group and dilution. (C) 
OD mapped to CFU counts using 10x dilution in the OD 0.1 and 1.0 range, and neat (undiluted) counts in 
the OD 0.01 range. (D) OD mapped to CFU counts using 10x dilution in the OD 0.1 and 1.0 range. Counts 
in the 0.01 group were adjusted for tissue-homogenate CFU signal depression by multiplying OD 0.01 
data-points by the ratio of average signal depression between 10x and neat dilutions in the OD 1.0 group 
(shown in B). (E) Best-fit linear regression for data in C. (F) Best-fit linear regression for data in D. All 




Figure 2.3: Gross images of formalin fixed lungs showing the dorsal aspect of the lungs. 
(A) Lungs from rabbits in the single exposure group show a spectrum of mild to moderate disease. (B) 




Figure 2.4: Timing of cavitation and cavity growth dynamics in the repeated aerosol method. 
(A) The frequency of cavitation over time. The solid line indicates the cumulative frequency of cavitation 
among the cohort of 9 rabbits. The dashed line indicates the frequency of cavitation among the cohort at the 
specific time point and is distinguished from the solid line by the occurrence of cavity resolution. (B) 
Cavity volume mapped to time after the start of infection for four representative cavities demonstrating (1) 
continuous growth, (2, 3) growth and shrinking behavior, and (4) growth and resolution. Cavities were 
identified as lung volumes not connected to the normal bronchial structure with densities between -875 and 
-1024 Hounsfield units and points on the x-axis indicating a non-cavitary focus are plotted at the limit-of-
resolution for the CT scanner. The y-axis is plotted using a logarithmic base 3 scale since measured volume 
varies closely as the cube of the radius of a spheroid object so that relationship among cavity volumes are 
more comparable to the two-dimensional reconstructions in C. (C) Transverse CT-scan reconstructions 
showing each of the foci identified in B. Transverse sections were chosen based on alignment of common 




Figure 2.5: Histologic patterns of tuberculosis lesions in rabbits infected by repeated aerosol exposure. 
(A) Representative H&E stained formalin fixed tissue slides demonstrating lesions commonly observed in 
rabbits infected by repeated aerosol exposure. (B) Serial sections from the boxed region demarcated in A 
stained with hematoxylin and eosin, acid-fast, and Masson’s trichrome stain. Masson’s trichrome identifies 
collagen in blue hues. (C) Overview of the model for collagenase mediated destruction of extracellular 




Figure 2.6: Collagen depletion in lung lesions of rabbits infected with Mycobacterium tuberculosis. 
(A) Examples of fields used for quantification of collagen enrichment. Black rectangles represent example 
high-resolution fields used for quantification in B and traces in C. (B) Relative enrichment in collagen 
identified by blue hues in the Masson’s trichrome stain. Surveys of collagen enrichment were random in 
normal appearing lung tissue and from regions 500 μm in length at the centers of lesion fields in 
granulomas and necrotic granulomas. Surveys of collagen enrichment from the cavity edge were defined as 
regions within 150 μm of the cavity edge. Multiple surveys were taken from non-overlapping areas within 
each region and the number above each category indicates the number of unique lesions surveyed. (C) 
Relative tissue density (grey line, right y-axis) and collagen density (black line, left y-axis) along linear 
traces crossing two granulomata, two necrotic granulomata, and two cavities. All traces are set to the same 
x and y scale as for the lower trace in E and the minor hash marks in E show the regular pattern of surveys 




Figure 2.7: Coomassie blue stained gel electrophoresis of collagen incubated in the presence of human 





Figure 2.8: Plasma concentration curves relating the concentration of cipemastat in rabbit plasma following 
a single oral dose of 100 mg cipemastat/kg body weight. 
(A) Graph showing traces for individual rabbits in the PK study. (B) Graph showing a curve representing 
the arithmetic means with standard-error bars of PK curves from the three rabbits shown in A. 
 
Figure 2.9: Experimental overview to investigate the pharmacologic inhibition of tissue destruction and 
cavitation using cipemastat in rabbits infected with Mycobacterium tuberculosis. The predicated temporal 





Figure 2.10: Collagen quantification in lung lesions of rabbits infected with Mycobacterium tuberculosis. 
(A) Average number of cavities per animal for weeks 7, 9, 12 and 14. (B) Average volume of the lung 
identified as cavity volume by CT-scan and segmentation analysis for weeks 7, 9, 12 and 14. (C) Disease 
severity scores of lungs assigned by two independent blinded observers. (D) Quantification of the fraction 
of lung identified as diseased by gross observation for rabbits in the single exposure and repeated exposure 
groups. (E) Example of a cavity wall showing regions identified as collagen. (F) Quantification of the 




Figure 2.11: Gross images of formalin fixed lungs showing the dorsal aspect of the lungs. 





Mechanical Action on the Necrotic 
Granuloma Drives Tuberculous 
Cavitation 
3.1 Background 
Despite the availability and efficacy of current anti-mycobacterial drugs, tuberculosis 
(TB) continues to be a significant cause of morbidity and mortality worldwide 3. To 
combat this persistent epidemic, research efforts have focused primarily on treatment and 
prevention with the development of new antibiotics and vaccines. However, the more 
difficult question of reducing transmission in high-burden countries has been 
insufficiently addressed. 30-50% of active TB infections result in the development of 
pulmonary cavities: abnormal air spaces surrounded by scar tissue which have replaced 
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the normal lung parenchyma 21. Though not unique to TB, cavitation plays a central role 
in the epidemiology of tuberculosis by driving transmission, treatment failure and drug 
resistance 5,6,8,21. The contribution of cavitation to the continued spread of TB makes it an 
attractive target for therapeutic intervention. However, despite the clear epidemiologic 
importance of cavitary disease, the pathophysiology of cavity development remains 
controversial.  
 
A major challenge in interrogating cavitary disease is that, of the available animal 
systems used to model TB, few develop spontaneous cavitary disease that shows 
phenotypic similarity to the human counterpart 13,14. Our lab has developed a reliable 
model of tuberculous cavitation using outbred New Zealand White rabbits infected with a 
serial low-dose exposure of Mycobacterium tuberculosis. This infection protocol was 
designed to mimic the pattern of human exposure in endemic environments. A high 
percentage of animals develop cavities by 7-9 weeks post-infection, and cavities display a 
high degree of phenotypic similarity to human cavitary lesions (Figure 3.1). Using high-
resolution computed tomography in combination with gross and histopathology, we are 
able to follow cavities in real time and gain insight into the dynamics of cavity formation. 
By utilizing this infection protocol in conjunction with high-resolution CT scans, we 




3.2 Current Theories 
The most widely accepted model of cavity formation proposes that cavities arise 
when large granulomas undergo central liquefaction, and subsequently erode into 
adjacent airways (Figure 1.1). Once in communication with the respiratory tree, these 
lesions discharge their liquefied contents, leaving behind an air-filled cavity. In this 
model, enzymatic proteolysis and matrix destruction are considered the major drivers of 
cavitation, and indeed, multiple matrix remodeling enzymes are known to be upregulated 
surrounding cavitary lesions 23,24,40–43. With this body of literature, matrix 
metalloproteinases (MMPs) have emerged as promising potential therapeutic targets. 
While MMP inhibition in animal models demonstrably reduces extracellular matrix 
(ECM) turnover 44, cavity formation has not been reduced by agents that block MMP 
activity in mice or rabbits 25,45. ECM depletion is expected to generate significant 
erosions into bronchioles and larger airways, and thus predicts sustained communication 
with the bronchial tree. Such cavities should have a well-aerated interior, with a similar 
gaseous composition to that of inspired air. However, studies by Haapanen et. al. 
revealed that a majority of human cavities have interior gas composition that is hypoxic 
and hypercarbic relative to alveoli, and frequently display either positive or negative 
internal pressure 46. These findings agree with earlier work by Coryllos and others, who 
demonstrated cavities frequently contain pressurized interiors 47. More recently, 
investigations by Belton et. al. revealed strong uptake of (18F)FMISO - an indicator of 
severe tissue hypoxia – in the consolidated region immediately surrounding pulmonary 
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cavities 48. These findings demonstrate that sustained bronchiolar communication is not 
reliably present in a majority of cavities.  
A second model of tuberculous cavitation proposes that cavities arise within the 
context of lipid pneumonia, independent of the granuloma. Drivers of cavitation in this 
model include bronchial obstruction by tuberculous pneumonia, and mycobacterial 
elaboration of cord factor 49,50. Support for this model is based largely upon human 
autopsy studies from the 19th and early 20th century. Consequently, is difficult to link the 
identified lesions at autopsy with pre-mortem, serial 3D radiologic imaging (eg, CT 
scanning) and thereby establish a chronology of events leading to cavitation. Importantly, 
lipid pneumonia has not been linked with cavitation in animal models, the majority of 
which reveal that cavitation occurs within the context of the caseating granuloma 
13,14,23,42. 
Finally, the role of mechanical forces in the context of pulmonary cavitation appears 
as a persistently unanswered question over many decades of TB literature 51–56 and has 
recently received renewed attention 57,58. The mechanical model of cavitation has its 
origins in the pre-antibiotic era, and postulates that cavitation is the result of the highly 
dynamic environment of the lung, which is subjected to constant motion and fluctuating 
pressures not experienced elsewhere in the body 33. Pioneers of this model were the 
research surgeons of the pre-antibiotic era, who utilized iatrogenic pneumothorax in order 
to “rest” the lung and allow closure of the cavity. Though invasive, this was frequently 
successful 53. This model is supported by the observation that cavities in man form 
preferentially in the apices of the lung, coinciding with the highest levels of pleural stress 
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33. Additional insight has been gained from comparisons to centrilobular emphysema and 
spontaneous pneumothorax, which have a similar preference for the lung apex 56,57. 
Similar to the lipid pneumonia model, the mechanical model emphasizes the role of 
bronchial obstruction with formation of one-way valves that allow air to enter a cavity 
but prevent its escape 47. Despite pulmonary mechanics being frequently cited as a 
probable contributor to cavitation, few investigators have attempted to clarify the role of 
mechanical stress in the pathogenesis of tuberculosis, likely due to limitations of current 
model systems. 
3.3 Methods 
Mycobacterial culture. Cultures of Mycobacterium tuberculosis H37Rv were 
growth from frozen stock aliquots in Middlebrook 7H9 liquid medium (Beckton 
Dickinson, Sparks, MD, USA) supplemented with 0.5% glycerol and 0.5% Tween 80.  
Animal infection. 20 SPF adult female New Zealand White Rabbits, weighing 3.5 – 
4.0 kg (Charles River Laboratories, USA and Robinson Services, NC, USA) were singly 
housed under Biosafety Level 3 conditions in accordance with protocols approved by the 
Institutional Animal Care and Use Committee at Johns Hopkins University, Baltimore, 
MD, USA. Infection was carried out using 5 low-dose aerosol exposures over a 2.5 week 
period using a Madison aerosol infection chamber (College of Engineering, University of 
Wisconsin, WI, USA). Delivery inoculum averaged 106 organisms per chamber cycle (6 
animals per cycle), and animals were randomized between inoculations to minimize inter-
cycle variability. This results in an implantation of approximately 500 CFU per animal 
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per exposure. CFU determination was calculated as previously described 13. Sensitization 
was confirmed in all animals five days after the final inoculation by intradermal injection 
of 0.1 mL mammalian Old Tuberculin in the right flank (Zoetis, Parsippany, NJ). 
Induration was read at 48 hours, and was quantified by calculating the average skin fold 
thickness in two dimensions multiplied by the ratio of the thickness at affected to 
unaffected sites. All animals were visually inspected daily for signs of illness, including 
respiratory distress, or reduction in appetite, urinary or fecal output. Animals were 
weighed bi-weekly, at which time they received brief physical examinations by a licensed 
veterinarian.  
Thoracic Computed Tomography (CT). Animals were sedated with intramuscular 
injections of xylazine (3 mg/kg), ketamine (25 mg/kg) and acepromazine (1 mg) prior to 
bronchoscopically–assisted intubation with a 3.5 mm endotracheal tube (Teleflex 
Medical, Research Triangle Park, NC). Following intubation, anesthetized animals were 
placed into a sealed chamber for transport to an imaging suite, where they were 
maintained on injectable anesthesia and 1-3 L/min oxygen. Breath-hold image acquisition 
was performed as previously described 22. Sedation was partially reversed with IV 
yohimbine (0.1 mg/kg) as needed. All animals were imaged at baseline (prior to 
infection), and then at 5, 7, 9, 11-12 and 14 weeks post-infection on a CereTom portable 
CT scanner (NeuroLogica, Boston MA). 
Image Processing. Raw CT scan data was compiled into DICOM files using Loening 
Amide (Version 0.9.0). All image analysis was performed using Invicro VivoQuant 
software (Version 2.50). Cavities were defined as having a central radiodensity matching 
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that of aerated lung (-1024 to -725 Hounsfield Units [HU]), surrounded by a radiodensity 
matching that of soft tissue (> -725 HU), which had a spherical morphology in three 
dimensions. Cavities that were not identified on at least two consecutive time points 
(including necropsy) were excluded from analysis to minimize the inclusion of 
radiographic artifacts. Gross photographs were analyzed in ImageJ (version 1.49, NIH, 
USA) by manually segmenting diseased lung and calculating extent of disease as the ratio 
of involved to uninvolved lung in ~5mm transverse lung sections. 
Necropsy and histopathology. IM sedation was performed as previously described, 
after which animals were euthanized with 2-3cc IV pentobarbital solution in the marginal 
ear vein. Immediately following euthanasia, the lungs were isolated and gently infused 
with 10% neutral buffered formalin prior to fixation. Tissues were fixed in 10% neutral 
buffered formalin for 48 hours, at which time they were serially sectioned, photographed 
and processed for histology. 5 μm paraffin-embedded sections were stained with 
hematoxylin & eosin (H&E), or Masson’s trichrome. Image capture for semi-automated 
quantification of trichrome staining was performed on a Nikon Eclipse 90i microscope 
with attached Nikon DS-Ri1 color camera, and analyzed using NIS Elements Advanced 
Research software (Version 4.50, Nikon Instruments, Melville, NY). Region of interest 
(ROI) selection was performed manually, and included the entire thickness of the cavity 
wall while excluding the interior air space. Positive staining was then calculated as a 
percentage of the total ROI. 
Statistical Analysis. All statistical analysis was performed with GraphPad Prism 
(Version 7.0, GraphPad Software, San Diego, CA). Single-variable data were analyzed 
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by nonparametric Kolmogrov-Smirnov test to compare cumulative distributions. Paired 
data were analyzed by nonparametric Wilcoxon test. Data sets containing three or more 
groups were analyzed by one-way ANOVA with Kruskal-Wallis test. Degree of 
correlation was calculated by liner regression with Spearman correlation coefficients and 
95% confidence interval. All error bars represent mean and standard deviation. 
3.4 Results 
Cavities show rapid expansion compared to solid caseous lesions. Cavitation was 
observed beginning at week 7 post-infection (PI), with the majority of cavities arising 
between 9-14 weeks PI. High inter-animal variability was observed in terms of disease 
severity and cavity generation, with 65% (13/20) of animals developing at least one 
cavity, and 69% (9/13) of those developing more than one cavity. Cavity size varied 
considerably, both within and between animals (Table 3.1). 
Cavitation was invariably preceded by a region of dense consolidation, identified 
as pulmonary regions with radiographic density matching that of non-aerated soft tissue 
(> -725 Hounsfield Units [HU]) (Figure 3.2A, 3.2B). To examine how cavities transition 
from these areas of solid consolidation, we compared total lesion volume (Vconsolidation + 
Vcavity) between sequential CT time points, with V2 representing the first appearance of 
the cavitary lesion, and V1 representing the region of consolidation at the time point 
immediately preceding cavitation. The V2:V1 ratio was then used to assess the rate of 
growth for each lesion. We discovered that cavity growth is rapid and abrupt, with cavity 
volumes ranging from 0.67 to 9.30 times the volume of the regions of consolidation from  
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Animal ID Cavity ID Week 7 volume Week 9 volume Week 12 volume Week 14 volume 
2 2.1 0 8.24 1.7 0.24 2.2 0 0 107.79 0.12 
3 
3.1 0 0.61 17.08 7.02 
3.2 0 0 10.29 4.24 
3.3 0 10.05 3.15 0 
4 4.1 0 0 0 188.92 
6 
6.1 0 0 15.62 14.65 
6.2 0 0 0 1.09 
6.3 0 4.97 0.48 7.51 
6.4 0 0 0 2.18 
10 10.1 0 208.42 75.93 4.84 10.2 0 133.09 19.13 9.57 
11 
11.01 0 0 0 1.93 
11.02 0 33.06 35.6 29.79 
11.03 0 0 0 1.7 
11.04 0 0 0 5.57 
11.05 0 0 0 1.21 
11.06 0 0 13.32 1.57 
11.07 0 7.75 5.69 17.8 
11.08 0 0.73 12.95 19.5 
11.09 0 0 10.78 1.45 
11.1 0 0 3.39 7.02 
11.11 0 0 50.86 7.63 
11.12 0 0 48.84 9.33 
11.13 0 0 34.27 8.48 
11.14 0 0.84 78.11 5.45 
11.15 0 0 0 33.06 
11.16 0 0 0 25.92 
11.18 0 1.7 17.08 0 
11.19 0 20.47 9.33 3.03 
13 13.1 0 0 0 0.48 13.2 0.48 2.06 12.84 0 
17 
17.01 0 0.24 274.3 1083.64 
17.02 0 0 22.89 63.34 
17.03 0 0 2.79 5.81 
17.04 0 0 13.32 0.73 
17.05 0 5.81 4.24 19.01 
17.06 0 0 0 2.42 
17.07 0 1.57 1.33 1.33 
17.08 0 0 1.57 5.57 
17.09 0 0 1.21 6.78 
17.1 0 0 0 41.41 
17.11 0 0 0 0.85 
Table 3.1: Changes in cavity volume over time. 
which they arise. On average, cavities were 1.87 times larger than their respective 
consolidated foci. We then compared this with the growth rates of solid, non-cavitary 
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lesions over the same time frame (sequential time points between weeks 7-14) using the 
above method. The behavior of solid lesions was significantly less dynamic, with growth 
rates ranging from 0.47 to 1.57. Surprisingly, 78% of non-cavitary lesions examined had 
a V2:V1 ratio less than 1, indicating that the majority of solid lesions shrunk over this 
time period. (Figure 3.2C). 
After formation, cavity behavior was highly variable, with cavities falling into one 
of three groups. The majority of cavities (17/32) were largest at the time of initial 
detection, and then progressively contracted over subsequent time points. A second group 
of cavities (8/32) underwent gradual enlargement from the time of detection. This group 
included several of the largest cavities. Finally, a third group (7/32) was characterized by 
small size (< 100 mm3) and dynamic behavior with alternating growth and shrinkage 
(Figure 3.2D). 4% of cavities (3/79) underwent complete resolution, becoming 
undetectable on both radiography and gross pathology. Remarkably, resolution did not 
correspond to any specific growth pattern. Of the three cavities that resolved completely, 
one fell into each of the above groups (growing, shrinking and dynamic). 
Disease is evenly distributed throughout the lung, but cavitation occurs at 
regions of high mechanical stress. As cavitary disease in human patients 
disproportionally affects the apices of the lungs, we sought to identify if cavities in 
rabbits also displayed a bias toward specific lung regions. Although there was no 
significant difference in the distribution of solid lesions in the lungs (Figure 3.3A), 
pulmonary cavities were unevenly distributed throughout the lung, with significantly 
more cavities forming in the caudal lobes (Figure 3.4A). In order to determine the effects 
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of transpulmonary pressures on cavity formation, a plane was drawn on CT images 
parallel to the course of the primary bronchi at the level of the tracheal bifurcation. This 
separated the lung into cranioventral (CV) and caudodorsal (CD) lung fields, 
corresponding to the sites of lowest and highest transpulmonary pressure in quadrupeds 
respectively 59. We found that significantly more cavities formed in the caudodorsal lung 
fields when compared to the cranioventral regions, on both a total and per-animal basis, 
with animals having roughly twice as many caudodorsal cavities on average (Figure 
3.4B). Cavities in the caudodorsal fields were also larger than those in the cranioventral 
regions, and associated with significantly more collagen deposition (Figure 3.4C, 3.4D). 
Irrespective of lung lobe, cavities usually (33/49) displayed a subpleural localization, 
where they were associated with varying degrees of pleural inflammation and fibrosis 
(Figure 3.4E). Surprisingly, despite frequent proximity to the pleural space, there was no 
evidence of cavitary rupture or pneumothorax, although occasional fibrinous adhesions 
between the visceral and parietal pleura were noted in several animals on postmortem 
examination. 
Cavitation occurs exclusively in the context of necrotizing granulomas with 
variable airway communication. Histologically, 100% (49/49) of examined cavities 
occurred within the context of organized granulomas, composed of discrete layers of 
epithelioid macrophages, multinucleated giant cells and lymphocytes, surrounded by 
fibroblasts and partially encapsulated in mature collagen. Cavitating granulomas were 
universally associated with central necrosis, as evidenced by a variably thick rim of 
acellular granular debris lining the cavity interior. Organized granulomatous 
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inflammation with central necrosis was a feature of all cavities examined, regardless of 
lesion age, size, morphology or location within the lung. While cavitation was invariably 
associated with necrosis, the converse was not true. Large necrotic granulomas without 
evidence of central cavitation were frequently visualized, suggesting that necrosis is 
necessary but not sufficient for the development of cavities (Figure 3.1C). Airway 
communication, defined as histologic continuity of the cavity interior with ciliated 
columnar respiratory epithelium, was detected in only 16% (8/49) of examined cavities 
(Figure 3.4E). These microscopic connections were below the limit of radiographic 
detection, and were not identified on computed tomography. As such, this figure likely 
underestimates the prevalence of bronchiolar communications. Based on gas and pressure 
analyses performed by Haapanen, roughly 33% of cavities are predicted to have sustained 
open communication with an airway 46. 
Our observations that rabbit tuberculous cavities (i) expand abruptly, (ii) appear 
subpleurally in the caudodorsal lung fields which experience the highest transpulmonary 
pressure, and (iii) form exclusively from pre-existing necrotic granulomas are consistent 
with cavity biogenesis resulting from acute tears in areas of necrotic tissue, with rupture 
into small airways and rapid subsequent gaseous filling. 
Cavities show divergent histomorphology with four discrete lesion types that 
provide mechanistic clues. Histologic examination of cavities revealed four distinct 
lesion morphologies (Figure 3.5A). The dominant morphology - designated as “smooth” 
– was characterized by a sharply-defined gas tissue interface at the cavity interior (Figure 
3.5B). This morphology was seen in over half of the cavities examined (27/49). The least 
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common morphology (“rough,” 4/49) had an interior cavity surface with an ill-defined, 
ragged gas-tissue interface (Figure 3.5C). A third type (“mixed,” 13/49) displayed 
characteristics of both rough and smooth cavities, with only a portion of the interior 
having the crisp and well-demarcated gas-tissue interface that defined smooth cavities 
(Figure 3.5D). The commonality of these three types was the relative thickness of the 
cavity wall. Smooth, rough and mixed cavities contained variable amounts of necrotic 
debris at the interior surface, and were surrounded by a thick wall of organized 
granulomatous inflammation. Finally, a small subset of cavities (5/49) – designated as 
“fibrous” - were characterized by large size and extremely thin walls composed almost 
entirely of mature fibrous tissue, and a slender, discontinuous inner rim of necrotic and 
inflammatory debris (Figure 3.5E). 
Next, we examined the relationship between lesion morphology and lesion age, 
defined as the time from first CT appearance of the cavity to the time of cavity resolution 
or necropsy. Unexpectedly, cavities with smooth or fibrous morphology represented the 
youngest lesions (Figure 3.5F). A potential confounder in this analysis is the fact that 4% 
(3/79) of cavities had resolved by the time of necropsy, making it impossible to define 
their cavity types. Thus it is possible that spontaneously resolving cavities belonged to a 
particular cavity type which would be underrepresented in the analysis above. 
All cavities were stained with Masson’s trichrome to assess the amount of collagen in 
each lesion as a percentage of the total cavity wall, which excluded air and necrotic 
debris at the cavity interior. Not surprisingly, fibrous cavities displayed the highest 
amount of collagen as a total percentage of their wall, but there was no significant 
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difference in collagen content among the other three cavity types (Figure 3.3B). 
Remarkably, the amount of fibrosis did not correlate with the age of the lesions (Figure 
3.3C). 
Tuberculin reactivity and disease severity do not predict the extent of cavitation. 
Previous work by Converse 17 and Kubler 22 demonstrated a weak correlation between the 
degree of tuberculin reactivity and the extent of cavitation using a small number of 
animals. In the present study, no significant correlation was found between induration 
and either the severity of disease or the number of cavities generated (Figure 3.6A, 3.6B). 
Somewhat unexpectedly, the extent of grossly-visible disease was also not predictive of 
cavitation, and animals with minimal disease occasionally generated large numbers of 
cavities (Figure 3.6C).  
3.5 Discussion 
Using a longitudinal imaging approach in combination with histopathology, we 
demonstrate that cavities expand rapidly upon development and then may resolve, 
continue to grow, or wax and wane in size. Far from being a new observation, the 
dynamic nature of cavities appears as a common source of frustration as far back as the 
early 1900’s, with Coryllos anthropomorphically relating their behavior as “capricious 
and puzzling 53.” When comparing the growth kinetics of cavities to solid lesions, it is 
apparent that there are mechanisms at work other than simple evacuation of interior 
contents. One would expect cavities growing by simple liquefaction and evacuation to be 
similar in size to the solid lesions that precede them. However, most cavities in this study 
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were several times larger than their corresponding precursor lesions, suggesting an 
explosive growth event. Additionally, the observation that most cavities are largest at the 
time of initial presentation strongly suggests that the onset of cavitation is an acute event, 
rather than a slow emptying of contents. The surprising observation that the amount of 
lesion fibrosis does not correlate with the age of the lesion confirms that remodeling of 
the fibrotic wall is similarly dynamic. 
In humans, cavitary lesions show a strong preference for the apices of the lung 12. 
Based on this distribution, it has long been presumed that cavities form preferentially at 
sites of high ventilation:perfusion (V:Q) ratios which favor bacterial growth 58. However, 
in addition to receiving the highest relative ventilation, the apices of the human lung are 
also the site of highest mechanical stress. Transpulmonary pressure (TPP), the “tension” 
force applied to the lung by negative pressure within the pleural space, follows a vertical 
gradient due to the interactions of gravity and thoracic wall shape. In humans, the area of 
greatest TPP therefore corresponds to the apices of the lung 33,56, while in quadrupeds, the 
caudodorsal lung fields experience the highest TPP 59. Meanwhile, V:Q ratios in animals 
are more uniformly distributed throughout the lung, owing to the effects of body posture 
on blood flow 60,61. This critical species difference has allowed us for the first time to 
tease apart the relative contributions of V:Q and TPP to the cavitation process.  
Our observation that rabbit tuberculous cavities are 2-fold more likely to form in the 
caudodorsal lung fields in the face of uniform disease indicates that TPP gradients play a 
significant role in determining cavity distribution. Additionally, these cavities are also 
larger, and display significantly increased collagen deposition when compared to those at 
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low TPP sites. This is likely due to the well-known effects of biomechanical instability 
on collagen deposition in damaged tissue 62,63. These results expand on the findings of 
Medlar and Sasano, who reported that maintaining infected rabbits in an upright posture 
alters the distribution of their disease to a more “human” phenotype with localization at 
the apices 64. Recent investigations by Casha et al. further emphasize the role of 
mechanical stress in human cavity development. Using computer modeling techniques, 
they demonstrate the profound effect that thoracic wall shape has on pleural stress, 
especially at the apex of the lung. In low BMI chests, they discovered up to a 10-fold 
increase in pleural stress at the apex, potentially explaining the increased incidence of 
cavitary TB in young males and individuals with low BMI 57.  
A majority of cavities in this study occurred subjacent to the pleura, further 
supporting the hypothesis that cavities occur at regions of structural weakness. Lesions 
occurring here are not surrounded by a buffer zone of elastic alveoli, but instead face the 
pleura which contains a higher proportion of inelastic collagen. In the face of high 
regional TPP, this area is predisposed to tears, evidenced by the high frequency of 
subpleural “blebs” and bullae in other pulmonary diseases such as emphysema 56,57. 
Studies of patients with pleural tuberculosis (arising from extension of subpleural lesions) 
report the incidence of subpleural cavitation at 50-60%, but the fraction of cavities which 
form subpleurally is unclear 65. Cavitation is not unique to TB, and may be caused by a 
diverse group of infectious etiologies as well as several neoplasms. The fraction of 
subpleural cavities has been documented for several other diseases, and in some 
infections approaches 100% 21. 
54 
 
Histologic examination of a large number of lesions revealed the existence of distinct 
cavity types. Over half of cavities displayed a sharply-demarcated gas-tissue interface, 
identical to those observed in the emergent C3HeB/FeJ mouse model of cavitation 42. 
Similar morphology has been referenced in detailed pathologic descriptions by Sweany 
and Seiler, who describe cavities with "smooth walls,” and provide photomicrographs of 
human cavities with clear “mixed” and “fibrous” morphology 66 (Figure 3.1D, 3.1E), 
confirming the translatability of findings in the rabbit model. This smooth histologic 
appearance is not pathognomonic but is distinctive of lesions where gas exerts pressure 
on surrounding tissue. Other diseases that share this morphology include Clostridial gas 
gangrene 67, decompression sickness 68, and gas bubble disease in aquatic species 69, in 
which the production or traumatic inoculation of gas bubbles produces the appearance of 
compressed tissue surrounding a central air space. The gross appearance of large gas 
bubbles dissecting through tissue planes 68 brings to mind Coryllos’s descriptions of a 
mucosa-like “glistening lining membrane” within many cavities, and also undeniably 
resembles the smooth shiny cavitary interior seen frequently in this model (Figure 3.1A). 
In the context of tuberculosis, these smooth-type cavities suggest a novel mechanism 
for cavity formation (Figure 3.7). The necrotic granuloma is fundamentally a sphere with 
a rigid fibrotic exterior and a soft caseous interior. Inspiration produces a rapid drop in 
pleural pressure, translating to the application of external tension and development of 
negative pressure within the sphere. Fibrous tissue is inelastic, and therefore prone to 
failure under repetitive mechanical stress. A tear occurring in the fibrotic wall that 
extended to the necrotic center would allow air to be sucked into the soft interior on 
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inspiration, with rapid subsequent enlargement of the lesion. Upon expiration, the tension 
force would be released resulting in positive pressure within the lesion and temporary 
closure of the tear. This is similar to the “one-way valve” theory postulated by Coryllos, 
Eloesser, and others, and explains the finding that cavities frequently contain pressurized 
interiors 47,53,54. Cavities with “smooth” morphology are younger on average, confirming 
that this most likely represents an early stage of cavitation. An extreme example of air-
trapping may also explain the presence of similarly young “fibrous” type cavities, with 
their large central space and thin walls reminiscent of balloons. Experiments by Coryllos 
in 1938 corroborate this mechanism by the introduction of a small diameter thoracoscope 
into human cavities and injection of small amounts of dye or saline. When suction was 
applied to the cavity interior, Coryllos observed a “bubbling of air” inward through the 
bronchial outlet, with simultaneous drainage of the instilled fluid. However, when 
positive pressure was applied, no movement of air or saline occurred, indicating that the 
outlet had been temporarily obstructed 47. 
Our findings strongly support a mechanism of cavitation driven by mechanical action 
on the necrotic granuloma. However, the question of the role of matrix remodeling 
enzymes in cavitary pathogenesis remains. In addition to driving a number of pathologic 
conditions, MMPs play an essential physiologic role in wound repair 70. Tissue injury by 
any means produces a secondary increase in matrix remodeling enzymes, and these 
elevations persist in the case of chronic non-healing wounds. Thus, elevated levels of 
MMPs and other ECM modifying enzymes may reflect their action as secondary 
responders to tissue injury, rather than primary drivers of cavitation. Regardless of the 
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initiating cause, it is likely that proteolysis and mechanical forces ultimately act in 
concert to produce tears in structurally weakened tissue.  
Investigative pathology necessitates a “snapshot” approach that often makes 
determining a sequence of events challenging, if not impossible. For this reason, 
precursor lesions were documented radiographically for each cavity, and used to 
determine growth kinetics. There has been extensive discussion of “liquefaction of the 
caseum” as the critical event preceding cavitation by Canetti, Dannenberg and many 
others 12,58,71, which has induced a decades-long search for the missing link in cavity 
pathogenesis. The lack of grossly liquefied caseum in this model (in contrast to high-dose 
bronchoscopic and M. bovis infection models) combined with the higher incidence of 
observed cavitation 25 argues against the existence of a transitional lesion requiring 
liquefied caseum. Our data suggest that a cavity is merely a traumatized necrotic 
granuloma, and predict that the lesion that gives rise to a cavity is histologically 
indistinguishable from any other caseating granuloma. This is supported by the 
observation that residual caseum within a cavity is microscopically identical to caseum 
inside a solid necrotic granuloma in both humans and rabbits 14 (Figure 3.1).  
In summary, this study employs a rabbit model of cavitation which produces a high 
frequency of human-like cavities, serial high-resolution CT scanning, and careful 
histopathologic analysis to chronicle the kinetics, distribution, and histologic types of 
tuberculous cavities. Our data support a mechanism of cavitation in which mechanical 
intrapulmonary forces act on the necrotic granuloma to produce a cavity. Although more 
studies are needed to confirm the findings here and their translatability to human patients, 
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elucidation of these mechanical factors may give additional insight on the lung-specific 
nature of cavitation. We also show further support that necrosis is an absolute 
prerequisite for cavitation. As intrapulmonary mechanical action cannot be easily altered, 






Figure 3.1: The rabbit model of tuberculous cavitation reliably produces lesions with a high degree of 
similarity to human cavities.  
(A) Transverse lung section showing gross pathology of a single subpleural cavity. The interior surface of 
the cavity is smooth and glistening. A small outlet is visible leading out of the cavity (arrowhead). (B) 
Histopathology of rabbit cavities shows homologous morphology to human cavities, with a central air 
space "*" surrounded by necrotic debris "N", layers of epithelioid macrophages "MO", and fibrous 
connective tissue with scattered lymphocytes "F". H&E. (C) Low-power view of a large necrotic 
granuloma without evidence of cavitation, despite close proximity to a bronchus “B”. Note the appearance 
of the central caseum, which is indistinguishable from casum lining a newly-formed cavity. H&E. (D) 
Photomicrograph of a pulmonary cavity from a human patient, showing “mixed” morphology. On the left, 
the interior surface of the cavity forms a sharply-demarcated gas-tissue interface. To the top and right, 
residual caseum at the cavity wall has begun to crumble. H&E. (E) Two walls of a “tension-type” or 
“bullous” cavity from a human TB patient, described as “thin plates of connective tissue.” A small amount 
of necrotic debris lines part of the cavity interior. Inflammatory cells are absent. H&E. D+E Reproduced 




Figure 3.2: Cavities arise rapidly from areas of pulmonary consolidation, and show highly dynamic growth 
kinetics. 
(A) Mid-thoracic transverse CT of an infected rabbit at week 7 post infection (PI) demonstrates a focus of 
pulmonary consolidation 4.4 mm in diameter, with no evidence of cavitation (circled). (B) Mid-thoracic 
transverse CT of the same animal at week 9, showing a large air-filled cavity present in the area of previous 
consolidation, measuring 8.8 mm in diameter (circled). (C) Growth rates of solid and cavitary lesions 
during week 7-14 PI, where V1 and V2 represent the lesion volume at two sequential timepoints. p< 0.0001 
(****), Kolmogorov-Smirnov paired t test. Mean & standard deviation (SD). (D) Growth dynamics of 
cavitary lesions during week 7-14 PI, where T1 represents the first appearance of the cavity, T2 and T3 
represent sequential timepoints following the cavitation event. Each colored line represents a single cavity. 
 
Figure 3.3: The amount of intralesional fibrosis does not correlate to lesion age or morphology. 
(A) Lesions are evenly distributed throughout all lung lobes. Each point represents a single animal. Disease 
fraction was determined by using 5mm thick cross-sections of fixed tissue and calculating the ratio of 
diseased to healthy tissue. (B) Collagen content of various cavity morphologies, assessed by trichrome 
staining and H&E. Mean & SD. (C) Collagen content of lesions of various ages as assessed by trichrome 




Figure 3.4: Cavities occur at regions of high mechanical stress, where they become larger and more 
fibrotic. 
(A) Distribution of cavities within the lung of TB-infected rabbits, enumerated by CT scan. Each point 
represents data from a single animal. Significantly more cavities form in the right and left caudal lobes. p < 
0.0001 (****), one-way ANOVA with Kruskal-Wallis test. Mean & SD. (B) Cavities preferentially form in 
the caudodorsal lung fields (CD) when compared to cranioventral lung fields (CV). Connected lines 
represent cavities in the same animal. p < 0.05 (*), Wilcoxon paired t test. Mean and SD. (C) Maximum 
volumes attained by cavities occurring in the CV or CD lung fields. p < 0.0001 (****), Kolmogorov-
Smirnov test. Mean and SD. (D) Percentage of the cavity wall composed of fibrotic tissue, calculated by 
positive trichrome staining (collagen). p = 0.0025 (**), Kolmogorov-Smirnov test. Mean and SD. (E) A 
majority of cavities are subpleural, and are associated with pleural inflammation and fibrosis. Few cavities 
display histologic evidence of airway communication (h= heart; *= cavity lumen; arrow= pleural surface; 




Figure 3.5: Histopathology reveals divergent cavitary morphology.  
(A) Histopathologic analysis of 49 cavitary lesions from 20 animals shows four distinct cavitary 
morphologies. (B) A “smooth” pulmonary cavity with a sharply defined gas-tissue interface, adjacent to a 
bronchiole. Hematoxylin & eosin (H&E). Inset, higher magnification of interior surface of cavity. (C) A 
large subpleural cavity with “rough” morphology, associated with focal pleuritis and pleural fibrosis. H&E. 
(D) A subpleural “mixed” cavity. The upper portion of the cavity has a smooth well-demarcated gas-tissue 
interface, while the lower portion is rough and ragged. The cavity has partially collapsed, leaving a dense 
band of fibrosis at the left aspect of the cavity. H&E. (E) A very large “fibrous” or “tension-type” cavity 
expands and obliterates the tip of a lung lobe, extending to both pleural surfaces. The wall is composed of 
mature fibrous connective tissue lined by scant necrotic debris and minimal cellular infiltrate. H&E. (F) 
Age of cavities based on serial CT scans and correlation with terminal histopathology. Mean and SD. 
 
Figure 3.6: Tuberculin reactivity is not predictive of cavitation or disease severity. 
(A) Scatter plot of the degree of induration at 48 hours following dermal old tuberculin and gross severity 
scores based on the percentage of lung affected. Each point represents an individual animal. R2 = 0.06. (B) 
Degree of induration at 48 hours plotted against number of cavities. R2 = 0.13. (C) Number of cavitary 
lesions plotted against gross severity scores. Note animals with extensive cavitation but minimal gross 
pathology. R2 = 0.02. Linear regression with Spearman correlation coefficients and 95 confidence interval 




Figure 3.7: Proposed mechanism of cavity genesis and progression. 
A cavity begins when mechanical action disrupts the necrotic granuloma by causing a tear in the fibrotic 
wall. With inspiration, external tension in the surrounding lung tissue pulls air into the necrotic center, 
causing a smooth cavity. If at any point the outlet is severely obstructed creating a ball-valve effect, 
extreme air trapping occurs and causes the cavity to assume a thin-walled fibrous balloon-like morphology. 
If the outlet is open or only partially obstructed, air accumulates less rapidly, resulting in smaller cavities 
which may progress or wax and wane. The mechanical actions of respiration continue to act on these 
lesions, causing eventual disruption and loosening of the retained caseum. This newly-freed material is 
coughed up in the sputum to continue the transmission cycle, leaving behind a mixed or rough cavity with a 
wall of progressively crumbling caseum. Finally, any of these lesions may spontaneously close and resolve, 






Mycobacterium Tuberculosis Induces 
Necroptosis in a Mouse Model of 
Necrotizing and Cavitary TB. 
4.1 Abstract 
Mycobacterium tuberculosis (MTB) manipulates host cell death pathways to 
complete its life cycle. Necrosis, a pro-inflammatory form of cell death, increases TB-
associated mortality by driving tissue destruction, antibiotic resistance and bacterial 
transmission. In vitro studies suggest that MTB exploits Receptor Interacting Protein 
(RIP) kinases to initiate host cell necroptosis – a form of programmed cell death - but 
translating these findings to animal models has been challenging, and the role of RIP 
kinases in vivo has been insufficiently explored. In the current study, C3HeB/FeJ mice 
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were infected aerogenously with 1.6 log10 colony forming units (CFU) of virulent MTB, 
and then received a novel RIP1 kinase inhibitor (GSK’547) delivered in chow, or 
nutritionally equivalent control chow from week 3 to 11 post-infection. Animals were 
sacrificed at two-week intervals for quantification of CFU, lung and serum cytokines, and 
immunohistopathology. Immunostaining for pMLKL – the final executioner of 
necroptosis – was strongly positive in macrophages within and around granulomas, 
confirming that necroptosis plays an important role during in vivo MTB infection. 
However, GSK’547 did not result in a reduction in pMLKL staining in treated animals. 
CFU counts, cytokines, and pathology also did not differ significantly between groups. 
These results confirm in vitro observations that necroptosis is induced by MTB during 
infection, but suggest that its induction may involve bypass of RIP1 kinase. 
4.2 Introduction 
The pathologic hallmark of MTB infection is the caseating granuloma, which is 
composed of a core of necrotic debris surrounded by layers of heterogeneous 
inflammatory cells and contained within a fibrotic capsule 26. Necrotic debris provides a 
rich bacterial growth medium which doubles as a barrier to antibiotic penetration, 
contributing to antibiotic resistance and treatment failure 72,73. Additionally, necrotic cell 
death is pro-inflammatory, releasing numerous chemical mediators that stimulate 
additional inflammation 74. This over-amplification of the immune response causes the 
bulk of TB-associated morbidity and pathology 75. Necrosis is also a prerequisite for the 
development of pulmonary cavities, the air-filled spaces left behind when a caseating 
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granuloma discharges its contents into an airway 26. As discussed in previous chapters, 
cavitation is the principle means of bacterial transmission, and has been identified as an 
independent risk factor for the emergence of drug resistant TB strains 6,7. Despite the 
immense importance of necrosis in the continued spread of TB, little is known about the 
pathways through which host necrosis occurs. Until very recently, necrosis was thought 
to be a disordered, unregulated, and unavoidable consequence of active infection. 
Necroptosis, a newly discovered form of programmed necrosis executed by RIP kinases, 
has immense implications for TB control. Multiple lines of evidence now suggest that 
MTB exploits RIP kinases to induce host necrosis 76–79. Thus, inhibition of RIP kinases 
has the potential to block this tissue destruction. Adjunctive therapies that inhibit host 
necrosis will lessen the global TB burden by reducing transmission, treatment failure, and 
antimicrobial resistance. 
4.3 Host cell death during MTB infection 
MTB is an obligate intracellular parasite that manipulates host cell death pathways to 
survive and propagate. Cells infected with MTB may undergo death by apoptosis or 
necrosis, a key divergence between attenuated and virulent TB strains 77. Apoptosis, a 
form of programmed cellular suicide, serves a host-protective role during TB infection by 
eliminating infected cells without triggering additional inflammation. Cells neatly 
package their disassembled contents into apoptotic bodies, which are then consumed by 
phagocytic cells. Apoptosis is most strongly induced by avirulent strains such as H37Ra, 
favoring bacterial control 77. Conversely, death by necrosis is lytic and messy, resulting in 
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uncontrolled release of cellular contents and infectious bacteria, both of which stimulate 
additional inflammation and tissue destruction 31. Although the ability to induce host cell 
necrosis is a defining characteristic of virulent MTB 80, little is known about the specific 
host mechanisms through which necrosis is induced or executed. 
The pro-inflammatory cytokine TNFα has been conclusively linked to necrosis during 
TB infection 81. TNFα is required for early bacterial control, and TNFα deficiency results 
in host cell necrosis due to overwhelming bacterial proliferation 82. However, high TNFα 
also results in host necrosis despite adequate control of bacterial growth, implicating 
TNFα as a major driver of TB immunopathology 76,81. Due to the serious risks of 
immunosuppression and disease reactivation during latent TB infection (LTBI), TNFα 
inhibition is not a viable strategy for adjunctive therapy during TB in human patients 83. 
However, the recent discovery of necroptosis, a form of programmed necrosis 
canonically induced by TNFα, has immense implications as the critical missing link 
between high TNFα and host necrosis during TB infection 84. 
Necroptosis is triggered in cells when apoptosis is stimulated while simultaneously 
blocked at a downstream checkpoint 85. This pathway was initially identified as a backup 
suicide mechanism for cells infected with viruses encoding caspase inhibitors, such as 
Herpesvirus 86. Other intracellular bacteria, including Listeria monocytogenes and 
Francisella tularensis also exploit the necroptotic pathway as a virulence strategy 87. 
Canonically, activation of necroptosis involves death receptor engagement by TNFα in 
the face of caspase inhibition, leading to the formation of a “necrosome” catalyzed by 
RIP1 and composed of multiple RIP3 subunits and the effector molecule MLKL (Figure 
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4.1) 88. Noncanonical activation occurs by interferon (IFN) stimulation, or through 
engagement of pattern recognition receptors (PRRs) such as TLR3/4 or DAI 89. 
Activation of the necrosome ultimately leads to cellular and nuclear membrane 
disruption, release of reactive oxygen species (ROS) and necrotic cell death 89. MTB 
produces multiple known apoptotic inhibitors (Figure 4.1) 90, and it is likely that virulent 
TB strains exploit necroptosis as a means of dissemination. In vitro studies in mouse and 
human macrophages have demonstrated that treatment with the RIP1 inhibitor 
Necrostatin-1s protects from necrotic cell death 78. However, translating these findings to 
in vivo models has been challenging 78.  
Recently, Roca et al. demonstrated that knock-down of RIP1 or RIP3 in Zebrafish 
infected with Mycobacterium marinum (a model system for examining the innate 
response to mycobacterial infection) leads to decreased bacterial burdens and reduced 
extracellular bacteria, further supporting the involvement of necroptosis in mycobacterial 
dissemination. They also demonstrated that pharmacologic inhibition of RIP1 achieves 
similar protection, teasing the possibility of necroptosis inhibitors as future adjunctive 
therapy for tuberculosis 76. Although overt histopathologic necrosis is not a feature of 
MTB infection in most mouse strains 91, studies by Zhao et al. revealed that RIP3-/- mice 
infected with M. tuberculosis exhibit reduced CFU counts when compared to wild type 
(WT) mice. This phenotype was shown to be transferrable by transplantation of RIP3-/- 
alveolar macrophages to immune-deficient mice 77. Despite mounting evidence that 
necroptosis impairs control of TB, the critical role of RIP1, the key decision checkpoint 
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and initiator of the necroptosis complex, has not been explored during in vivo MTB 
infection. 
Elucidation of the role of RIP1 in vivo has been hindered by a lack of genetic tools, 
with RIP1-/- mice dying shortly after birth 92. As different cell types display widely 
differential susceptibility to necroptosis induction 78,93, conditional or tissue-specific 
knockout animals are likely to underestimate the effects of necroptosis in inflammation 
and tissue destruction. Although a handful of RIP1 inhibitors have recently been made 
commercially available, these drugs exhibit significant off-target effects and poor 
pharmacokinetic properties, making them unsuitable for long-term in vivo dosing 94. 
4.4 Mouse models of necrotizing pulmonary TB 
Until recently, mice have been overlooked as models of necrotizing pulmonary TB, 
since commonly used mouse strains do not form the caseating granulomas characteristic 
of the infection in humans 91. However, immunocompetent C3HeB/FeJ mice develop 
highly organized, encapsulated hypoxic and necrotic lesions following TB infection 28,95. 
Importantly, these lesions are much more representative of the observed pathology in 
human TB patients than those generated by a majority of other mouse strains. TNFα 
inhibition in conjunction with standard antibiotic therapy results in a significant reduction 
in both CFU counts and necrotic pathology, confirming TNFα as a major mediator of 
necrosis in this model 96. However, due to the serious risk of disease reactivation during 
latent TB infection (LTBI), TNFα inhibition is not a viable strategy for adjunctive 
therapy during TB in human patients 82.  
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The high susceptibility of C3HeB/FeJ mice to TB infection is associated with the 
“super-susceptibility to tuberculosis-1” (sst1) locus on chromosome 1. The sst1 locus was 
recently discovered as a key genetic determinant of necrotic pathology in the C3HeB/FeJ 
mouse, but the exact mechanism through which this occurs is currently unknown 31. The 
sst1 locus contains the newly-identified IPR1 (intracellular pathogen resistance) gene 
which is involved in modulating the host response to intracellular stress 30,31. The mode 
of death in sst1-susceptible macrophages shares many similarities with RIP1-mediated 
necroptosis (Table 4.1), including substantial overlap in the initiators (TNFα and type I/II 
IFNs), mediators (JNK, PKR), and executioners (reactive oxygen species [ROS], 
mitochondrial permeability) 32,85. Interestingly, sst1-susceptible cells are also 
hypersusceptible to Listeria monocytogenes and Francisella tulirensis, two bacterial 
pathogens which also exploit necroptosis as a mechanism of virulence 87. As with 
necroptosis, blockage of sst1-mediated necrosis shifts cells to apoptotic death 32. We 
hypothesize that IPR acts as a brake on necroptosis during MTB infection, and that 
pharmacologic inhibition of RIP1 will alleviate necrosis in this model. 
 Sst1-mediated death RIP1-mediated death 
Induction TNFα Type I, II IFN 
TNFα (canonical) 
Type I, II, IFN, 
TLR3/4, DAI, etc. (noncanonical) 
Mediators ROS RIP1, RIP3, MLKL, ROS 
Inhibition 









Morphology Mitochondrial disruption, necrosis Mitochondrial disruption, necrosis 
Table 4.1: There is extensive overlap between RIP1-mediated and sst1-mediated necrosis. Both result in 
necrotic cell death as a result of mitochondrial membrane disruption and release of reactive oxygen species 
(ROS). Multiple initiators and mediators are shared between the two pathways. Finally, inhibition of both 




Mouse infection. 140 female C3HeB/FeJ mice (Jackson Labs, Bar Harbor ME) were 
obtained at 6-8 weeks of age and allowed to rest for one week after introduction to the 
facility. Animals were grouped housed under Biosafety level 3 conditions in accordance 
with protocols approved by the Institutional Animal Care and Use Committee at Johns 
Hopkins University (Baltimore, MD, USA). Mice were infected directly from a frozen 
stock of Mycobacterium tuberculosis H37Rv using an aerosolization system (Glas-Col 
Inc., Terre Haute, IN, USA). Animals in one cohort received GSK’547 formulated into 
chow from weeks 3-11 post infection, while those in the control cohort received 
equivalent non-medicated chow (Purina Research Diets, New Brunswick NJ, USA). 
Animals were weighed weekly to assess for disease-related weight loss. 
CFU and cytokine determination. Six mice were sacrificed on day one post-
infection for enumeration of implantation colony forming units (CFU). For CFU counts, 
lungs and spleens were isolated and ground into a homogenate before being serially 
diluted and grown on 7H11 selective agar (Becton Dickinson, Franklin Lakes, NJ, USA) 
for a minimum of three weeks. Blood and bronchoalveolar lavage fluid (BALF) were 
collected immediately post-mortem. Blood was collected via cardiac puncture and 
allowed to clot at room temperature before centrifugation. BALF was collected by 
instilling 500 ul of sterile PBS into the cervical trachea, followed by syringe aspiration of 
the instilled fluid. This was repeated once, resulting in 1mL total volume lavage fluid per 
lung. Lungs used for BALF collection were used exclusively for histopathology, and not 
for CFU determination. Serum and BALF were passed through a 0.22 um PES syringe 
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filter (Thermo Scientific, Waltham, MA, USA) to remove Mycobacteria. IL-1beta, IL-2, 
IL-6, IL-10, IL-12, TNF alpha, and IFN gamma were quantified using the Bio-Plex Pro 
Mouse Cytokine Th1 Panel (Bio-Rad, Hercules CA, USA). IFN-beta concentrations were 
determined using the Mouse IFN-beta Quantikine ELISA (R&D systems, Minneapolis, 
MN, USA). 
Histopathology & immunofluorescence. Following sacrifice, lungs were instilled 
with 600-800 ul of 10% neutral buffered formalin (NBF) before fixation. After 48 hours 
of fixation, lungs were processed and paraffin-embedded whole, cut into 5 um coronal 
sections and stained with hematoxylin and eosin (H&E), or processed for 
immunofluorescence. Heat-induced epitope retrieval was performed in citrate buffer at 
pH 6. Blocking with TBST+ 5% normal goat serum was performed prior to 
permeabilization using .1% Triton X-100 in TBST for 10 minutes. Samples were 
simultaneously incubated with primary antibodies diluted with TBST+ 5% normal goat 
serum for 1 hour, followed by incubation with directly-conjugated primary antibody and 
secondary antibodies diluted with TBST to 2 ug/ml for one hour. Primary antibodies: 
anti-phospho-MLKL 196436 (Abcam, Cambridge, MA), anti-Vimentin 300-223 (Novus 
Biologicals, Centennial, CO), anti-CD68 201844 (Abcam, Cambridge, MA). Secondary 
antibodies: anti-rabbit 175471 (Abcam, Cambridge, MA), anti-chicken 150171 (Abcam, 
Cambridge, MA). Fluorshield Mounting Medium with DAPI (Abcam, Cambridge, MA) 
was used for coverslipping and staining. Slides were viewed using a Nikon Eclipse TI 
confocal microscope with attached Nikon AI camera. Images were compiled and edited 
in ImageJ (version 1.49, NIH, USA). Stained slides were digitized with Aperio 
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ScanScope (Leica Biosystems, Buffalo Grove, IL, USA) and analyzed using Aperio 
Image Scope (v12.3.2.8013, Leica Biosystems, Buffalo Grove, IL, USA). 
Minimum Inhibitory Concentration (MIC) of GSK’547. An Alamar Blue viability 
assay was performed using M. tuberculosis H37Rv grown in liquid 7H9. Aliquots of 
MTB were grown for 7 days in broth culture prior to drug application. GSK’547 was 
compared to isoniazid (INH) and untreated controls to determine the IC-50. 
4.6 Results 
The C3HeB/FeJ mouse is a model of necrotizing and cavitary pulmonary 
tuberculosis. C3H3B/FeJ mice are uniquely susceptible to Mycobacterium tuberculosis, 
and respond to infection by developing extensive pulmonary necrosis. This results in the 
development of large caseating granulomas characteristic of the disease in humans, but 
not seen in other commonly used mouse strains 91. To further characterize the 
development of necrosis in this model, we infected 140 C3HeB/FeJ mice with virulent 
MTB via aerosol. Infected mice reliably developed a spectrum of lesions, ranging from 
macrophage-rich pneumonia to organized granuloma formation, to formation of large 
caseating necrogranulomas (Figure 4.2A). Cavitation was occasionally seen, always 
originating within large necrotic lesions. The observation of cavitation in this model 
further confirms necrosis as a critical event preceding cavitation, as cavitation has not 
been documented in other rodent models of MTB infection 42,97. 
Mycobacterium tuberculosis infection stimulates phosphorylation of MLKL in 
vitro. To establish if necrosis in this model occurs as a result of RIP-mediated 
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necroptosis, we infected mice with a low-dose of aerosolized MTB and performed 
immunofluorescent staining for phosphorylated MLKL (pMLKL), the final effector of 
necroptosis. Robust phosphorylation of MLKL was seen throughout the lungs of infected 
mice surrounding large necrotic granulomas (Figure 4.2B) and in regions of macrophage-
rich inflammation (Figure 4.2C), with minimal positive staining in regions of 
histologically normal lung. Staining for CD68 and vimentin was performed 
simultaneously to determine the cellular compartmentalization of pMLKL. Cytoplasmic 
aggregates of pMLKL were seen primarily within CD68+ macrophages (Figure 4.2B, 
4.2C), and to a lesser extent in vimentin+ fibroblasts and non-labeled cells (not shown).  
GSK’547 monotherapy does not protect from MTB-induced pulmonary 
necrosis. Due to the presence of robust MLKL phosphorylation indicating activation of 
necroptosis, we hypothesized that inhibition of RIP1 kinase would inhibit necroptosis and 
alleviate severe lung pathology in this model. RIP1 kinase, the key decision checkpoint 
downstream of TNFα stimulation, is composed of three domains – a kinase, intermediate, 
and death domain 92. While the kinase domain is required for initiation of necroptotic 
death, it is dispensable for NF generation, making RIP1 an attractive therapeutic 
target 98. A handful of well-characterized RIP1 inhibitors have emerged in the past 
several years, but very few have been utilized in animal models. Necrostatin-1s, the most 
potent available RIP1 inhibitor, has a short half-life and shows significant off-target 
effects, making it unsuitable for long-term in vivo dosing 94. Our collaborator Dr. John 
Bertin has developed GSK’547: a next-generation RIP1 inhibitor that demonstrates 
superior potency and selectivity over Necrostatin-1s, significantly limiting its off-target 
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effects. GSK’547 achieves greater than 90% RIP1 inhibition within 24 hours when 
administered to mice in chow, and is suitable for long-term dosing (data not shown).  
To examine the role of RIP1 during in vivo TB infection, C3HeB/FeJ mice were 
infected with a low dose (1.6 log CFU) of aerosolized MTB and treated with the novel 
RIP1 inhibitor GSK’547 or vehicle control from week 3-11 post infection. Grossly, lungs 
from treated animals were indistinguishable from controls at weeks 5, 7, 9 and 11 (Figure 
4.3A). For microscopic analysis, digital quantification of inflammation and necrosis was 
performed on H&E stained lung sections. Somewhat surprisingly, these parameters were 
not improved by GSK’547 treatment. The percentage of affected to unaffected lung tissue 
was similar in both groups, averaging approximately 30% (Figure 4.3B), while the 
percentage of necrosis in treated animals was slightly higher on average (Figure 4.3C). 
We next sought to determine if GSK’547 treatment had any effect on lesion phenotype by 
measuring the size of both inflammatory and necrotic lesions. Inflammatory lesions 
varied considerably in size within individual animals, but did not differ between groups 
(Figure 4.3D). Necrotic foci displayed less variability with the exception of one 
individual, and were also similar between treated and untreated animals (Figure 4.3E).  
GSK’547 does not impact mycobacterial survival. To determine if GSK’547 is 
able to directly influence mycobacterial survival, a colorimetric cell viability assay was 
performed, using isoniazid, a first-line antomycobacterial drug as a positive control. We 
confirmed that GSK’547 lacks antimycobacterial activity in vitro at all concentrations 
tested, up to 64 ug/mL. As host necrosis is known to promote the propagation of MTB in 
vivo, we hypothesized that necrosis inhibition by GSK’547 would indirectly decrease 
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mycobacterial proliferation. To determine if GSK’547 influences mycobacterial survival 
in vivo, colony forming unit (CFU) counts in the lung and spleen were performed over 
the course of infection. After 11 weeks, GSK’547 monotherapy had no effect on the 
bacterial burdens in either the lungs or spleens of infected mice (Figure 4.4A, 4.4B). At 
the time of sacrifice, spleen weights were measured to serve as an estimate of overall 
systemic immune activation. Spleen weights were similar between groups at all time 
points, indicating similar magnitudes of systemic immune activation in both treated an 
untreated animals (Figure 4.4C). Weight loss was observed in the treatment group at the 
onset of treatment, but all animals appeared healthy and gained weight appropriately 
throughout the study (Figure 4.4D), suggesting a palatability issue rather than a direct 
effect of the drug. 
GSK’547 does not significantly alter cytokine profiles of infected mice. The role 
of RIP1 in necroptosis is dependent on its kinase domain, as phosphorylation and 
activation of Rip3 by Rip1 promotes downstream MLKL phosphorylation and necrotic 
cell death (Figure 4.1). However, RIP1 has pleotropic functions, and can also serve a pro-
survival role in the cell. During pro-inflammatory signaling, RIP1 is ubiquitinated 
(multiple domains) and serves a scaffolding function in NFkB generation through the 
intermediate domain 92. To examine the effect of RIP1 inhibition on pulmonary and 
systemic immune responses, cytokines were quantified in both serum and 
bronchoalveolar lavage fluid (BAL) of infected mice, and then compared to uninfected 
controls (Figure 4.5). Levels of IFNγ, IL-6, IL-12 and IL-10 did not differ significantly 
from controls in either BAL fluid or serum. Serum levels of IFNγ, the principle cytokine 
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of MTB control, decreased in all groups from weeks 7-11 (Figure 4.5A, potentially 
signaling the onset of the Th1 dysregulation that characterizes severe disease. Cytokine 
levels overall were higher in BAL samples than in serum, suggesting local pulmonary 
cytokine concentrations may give a more representative picture of immune status during 
MTB infection than serum profiling. Total cytokines recovered from BAL fluid were also 
relatively low, and future analyses may benefit from use of tissue homogenates. Serum 
and BAL levels of TNFα, IL-1β, IL-2 and IFNβ were below levels of detection at all time 
points (data not shown).  
4.7 Discussion 
Necroptosis, mediated by Receptor Interacting Protein (RIP) kinases, has been 
implicated in the pathogenesis of MTB-induced host cell death in vitro 76–78, but 
appropriate in vivo models are currently lacking. We demonstrate for the first time that 
the C3HeB/FeJ mouse, a recently characterized model of necrotizing and cavitary 
pulmonary tuberculosis 42, undergoes MTB-induced necroptosis. We observed robust 
MLKL phosphorylation within pulmonary macrophages of C3HeB/FeJ mice in response 
to low-dose aerosol MTB infection, confirming the execution of necroptosis in these 
cells. This contrasts sharply with the findings of Stutz et al, who report that MLKL 
phosphorylation is not a feature of macrophage death in vivo using C57B/6 mice99. This 
may reflect an important strain difference, as C57B/6 do not generate necrotic lesions 
when infected with MTB 91. Additionally, we observed pMLKL staining to a lesser 
extent in vimentin+ fibroblasts and unlabeled cells. Consistent with the majority of in 
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vitro data 77,78, this confirms macrophages as the major, but not exclusive cell population 
to undergo MTB-induced necroptosis during infection.  
Having established the C3HeB/FeJ mouse as an in vivo model of MTB-induced 
necroptosis, we next sought to utilize this model to test novel pharmacologic inhibitors of 
necroptosis. Despite evidence of robust necroptosis activation, the novel RIP1 inhibitor 
GSK’547 failed to protect mice from necrotic pathology and had no effect on bacterial 
replication. Although this seems to contradict the established in vitro literature, there are 
several possible explanations for GSK’547’s observed lack of effect. Poor penetration of 
chemotherapeutics into necrotic and fibrotic tuberculous lesions is a problem both in 
human patients and animal models 72. Although the concentration of drug administered in 
this study was chosen to achieve 90% RIP1 inhibition within 24 hours based on PK 
studies conducted at GlaxoSmithKline, it is possible that drug concentrations did not 
reach adequate levels in granulomatous tissue due to poor penetration. Future studies will 
focus on quantifying the amount of drug within lesional tissue in order to confirm 
adequate drug exposure.  
RIP1, required for canonical necroptosis activation, is dispensable in several 
alternatively activated pathways such as those shown in Figure 4.1 89. It is possible that 
necroptosis activation in MTB-infected macrophages proceeds through one of these 
alterative pathways. Recently, Niederweis et al demonstrated one such RIP1 bypass 
pathway induced by Tuberculosis Necrotizing Toxin (TNT), an NAD glycohydrolase 79. 
TNT, produced by virulent MTB, induces necrosis through host cell NAD depletion, 
which is sufficient to cause RIP3 and MLKL activation in THP-1 macrophages 79. Taken 
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together with our findings, this suggests that MTB is able to activate necroptosis 
independently of the canonical RIP1-TNF axis. However, induction is likely dependent 
on host cell type, as demonstrated by Butler et al, who showed that RIP1 activation is a 
feature of in vivo macrophage death in many, but not all cell lines infected with MTB 78. 
Interestingly, THP-1 macrophages were classified as resistant to TNF/RIP1 induced cell 
death during infection in these experiments 78. 
The last decade has seen an explosion of cell death-related research, resulting in the 
discovery and characterization of numerous programmed death pathways 84. As the first 
to be discovered, RIP-mediated necroptosis remains the most well-characterized, and is 
considered the prototype of regulated necrosis. However, other novel forms of 
programmed cell death are still being elaborated. Several of these, including pyroptosis, 
ferroptosis 100, and ETosis 101 have also been implicated in the pathogenesis of 
mycobacterial-induced cell death 102. Significant interactions and redundancies between 
these and other known pathways are becoming apparent, further complicating our 
understanding of the host-pathogen relationship during cell death and underscoring the 
necessity of a multi-modal collaborative approach 102. Elucidation of the role of RIP1 in 
vivo has been hindered by a lack of genetic tools, with RIP1-/- mice dying shortly after 
birth. Genetically engineered mice (GEMs) expressing catalytically inactive RIP1 have 
recently been established 103. Unlike their RIP1-/- counterparts, these mutant mice are 
viable, fertile, and free of background pathology 103. In the future, these mice will allow 
us to clarify the role of RIP1 during MTB infection. Additionally, cross breeding of RIP1 
kinase-dead mice with other susceptible strains such as the C3HeB/FeJ or the newly 
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characterized B6J.C3-sst1C3HeBFeJKrmn (a resistant C57B/6 mouse bearing the 
C3HeB/FeJ susceptibility locus) 32 will provide valuable information about the role of 
RIP1 kinase in the genetic susceptibility to tuberculosis. 
In summary, we demonstrate that pulmonary macrophages of C3HeB/FeJ mice 
undergo robust MLKL phosphorylation during in vivo MTB infection – confirming 
necroptosis execution in these cells. Although the novel RIP1 inhibitor GSK’547 failed to 
protect from necrotic pathology in this study, the C3HeB/FeJ mouse model provides a 
valuable tool for investigating novel host-directed therapies. As very few rodent models 
develop overt necrosis in response to MTB infection 27, the C3HeB/FeJ is essential for 







Figure 4.1: Interactions between MTB and the necroptotic pathway.  
RIP1 is the key decision checkpoint regulating cell death downstream of TNFα. Outcomes are highly 
context-dependent, and include 1) cell survival through ubiquitination of RIP1 and transcription of NFkB, 
2) apoptosis through Caspase 8 activation and RIP1/RIP3 inactivation, and 3) necroptosis through 
inactivation of Caspase 8 and formation of the necrosome catalyzed by active RIP1. MTB employs 
multiple strategies to block apoptosis and promote necroptosis. These include production of soluble TNFα 
inhibitors, inhibition of caspase 8 at the level of transcription or expression, and induction of FLIP, an anti-




Figure 4.2: MTB infection stimulates pulmonary necroptosis in C3HeB/FeJ mice. 
(A) A single large necrogranuloma in the lung of an infected C3HeB/FeJ mouse, typical of lesions in this 
strain. (B) C3HeB/FeJ mice infected with a low dose of MTB (1.6 log CFU) show strong positive 
cytoplasmic immunostaining for phosphorylated MLKL in CD68-positive macrophages surrounding 
necrotic granulomas. The necrotic center is in the lower right corner of the image. 40x.  (C) Robust 





Figure 4.3: The novel RIP1 inhibitor GSK’547 does not protect from MTB-induced necrotic lung 
pathology in C3HeB/FeJ mice. 
(A) Gross photographs of mouse lungs at week 11 post-infection. C3HeB/FeJ mice generate large caseating 
granulomas which are grossly visible as white/tan foci. Gross pathology is indistinguishable between 
vehicle-treated (top) and GSK’547-treated animals (bottom). (B) Digital quantitation of lung inflammation 
as a percentage of total section area on H&E at week 9 post-infection. (C) Digital quantification of lung 
necrosis, shown as a percentage of inflammation on H&E at week 9 post-infection.  There is trend toward 
increased necrosis in treated animals. (D) Average size of inflammatory lesions in C3HeB/FeJ mice.  Each 
bar represents data from a single animal. (E) Average size of necrotic lesions in C3HeB/FeJ mice.  Each 




Figure 4.4: GSK’547 treatment does not impact mycobacterial survival in vivo. 
(A) Bacterial burden in the lungs of infected animals, shown as the number of colony forming units (CFU).  
Mean and SD. (B) Bacterial burden in the spleens of infected animals.  Mean and SD. (C) Terminal spleen 
weights as an estimation of systemic immune activation.  Due to differences in body weight, spleen weight 
was normalized to body weight for each animal.  Mean and SD. (D) Body weights over the course of 




Figure 4.5: Local and systemic cytokine profiles during MTB infection. 
Quantification of cytokines from bronchoalveolar lavage (BAL) fluid of C3HeB/FeJ mice at week 9 post-





AUC .................................Area under the curve 
BAL, BALF .....................Bronchoalveolar lavage fluid 
BCG .................................Bacillus Calmette-Guérin 
BMI ..................................Body mass index 
BSL# ................................Bio-safety Level 
CD ....................................Caudodorsal 
CD# ..................................Cluster of differentiation 
CFU ..................................Colony forming units 
Cmax ................................Concentration maximum 
CMI ..................................Cell Mediated Immunity 
CT ....................................Computed tomography 
CV ....................................Cranioventral 
DTH .................................Delayed type hypersensitivity 
ECM .................................Extracellular matrix 
EDTA ...............................Ethylenediaminetetraacetic acid 
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GEM .................................Genetically engineered mice 
H&E .................................Hematoxylin and Eosin 
HDT .................................Host-directed therapy 
HIV ..................................Human Immunodeficiency Virus 
HU ....................................Hounsfield units 
IC50..................................Half maximal inhibitory concentration 
IFN ...................................Interferon 




IPR ...................................Intracellular pathogen resistance gene 
IV .....................................Intravenous 
LC/MS-MS ......................Liquid chromatography/Tandem mass spectrometry 
LTBI .................................Latent TB infection 
MIC ..................................Minimum inhibitory concentration 
MLKL ..............................Mixed Lineage Kinase-Like Protein 
MMP# ..............................Matrix metalloproteinase 
MTB .................................Mycobacterium tuberculosis 
NBF ..................................Neutral buffered formalin 
NHP..................................Non-human primate 
NZW ................................New Zealand White 
OD ....................................Optical density 
PI ......................................Post infection 
PK ....................................Pharmacokinetic 
pMLKL ............................Phosphorylated MLKL 
PPD ..................................Purified protein derivative 
PPE ...................................Personal protective equipment 
PRR ..................................Pattern recognition receptor 
RIP, RIPK ........................Receptor Interacting Protein Kinase 
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ROI ...................................Region of interest 
ROS ..................................Reactive Oxygen Species 
sst1 ...................................Super susceptibility to tuberculosis-1 locus 
TB ....................................Tuberculosis 
Th# ...................................T helper 
Tmax ................................Time maximum 
TNFa ................................Tumor necrosis factor alpha 
TNT ..................................Tuberculosis necrotizing toxin 
TPP ...................................Transpulmonary pressure 
V:Q ...................................Ventilation to perfusion ratio 
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